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Abstract
Cytochrome P450 metabolises N,N-dialkylamides to their corresponding N- 
dealkylated products via the formation of an N-hydroxyalkyl-N-alkylamide 
intermediate. Studies by Iley et. al. have shown that the oxidative dealkylation of these 
amides occurs via hydrogen abstraction from the alkyl carbon atom a- to the amide 
nitrogen. This leads to the formation of a carbon-centred radical; it is believed that this 
radical is the cause of toxicity for these amides. The amide solvents, HMPA and 
DMPU have similar functional groups. Because of this similarity it is believed that 
HMPA and DMPU may undergo an analogous metabolic pathway to that of 
previously studied amide solvents.
Interestingly HMPA is toxic whereas DMPU is not. Investigation into why this is the 
case would be of use in designing other non-toxic solvents. This model study has 
shown that methyl group oxidation in HMPA is subject to a deuterium isotope effect 
of -10. This would imply that H-atom abstraction occurs with the formation of a 
highly reactive C-centred radical. A deuterium isotope effect was not attempted for 
DMPU, but product analysis showed single oxidation of the ring to form 4-hydroxy-
l,3-dimethyltetrahydropyrimidin-2-one and subsequent oxidation to afford 1,3 
dimethyl-5,6-dihydropyrimidine-2,4-dione.
Abbreviations
HMPA
PMPA
FPMPA
TetraMPA
TriMPA
FTetraMPA
DMF
NMF
DMBA
NMBA
DMPU
TMSCl
TFA
TPPFeCl
TPPMnCl
'BuOOH
'BuOH
ACN
DCM
THF
AHf
AG^
hexamethylphosphoramide
pentamethylphosphoramide
N-formylpentamethylphosphoramide
tetramethylphosphoramide
N,N',N"-trimethylphosphoramide
N-formyl-N,N,N',N"-tetramethylphosphoramide
N,N-dimethylforaiamide
N-methylformamide
N,N-dimethylbenzamide
N-methylbenzamide
l,3-dimethyl-3,4,5,6,-tetrahydro-2(lH)-pyrimidin-2-one previously 
known as dimethylpropylurea 
trimethylsilyl chloride 
trifluoroacetic acid
5.10.15.20-tetraphenyl-21H,23H-porphine iron(III) chloride
5.10.15.20-tetraphenyl-21H,23H-porphine manganese(III) chloride 
rerT-butylhydroperoxide
tert-h\ximo\ 
acetonitrile 
dichloromethane 
tetrahydrofuran 
heat of formation 
Gibb’s free energy
AAG  ^ difference in Gibb’s free energies
FAD flavin adenine dinucleotide, oxidised form
FADH2 flavin adenine dinucleotide, reduced form
FMN flavin adenine nucleotide, oxidised form
FMNH2 flavin adenine nucleotide, reduced form
NAD? nicotine adenine dinucleotide phosphate, oxidised form
NADPH nicotine adenine dinucleotide phosphate, reduced form
GC gas chromatography
GCMS gas chromatography mass spectrometry
HPLC high performance liquid chromatography
UV ultra-violet spectroscopy
IR infra-red spectroscopy
MS mass spectroscopy
m.p. melting point
M.O. molecular orbital
MTBSTFA N-methyl-N-re/t-butyldimethylsilyltrifluroacetamide 
P450cam bacterial cytochrome P450 responsible for the metabolism of camphor 
DIB AL diisobutylaluminium hydride
DIAD diisopropyl azodicarboxylate
1 Introduction
1.1 Enzymology
In 1958 Klingenburg^ and Garfinkel  ^ independently reported a pigment in liver 
microsomes which, when carbon monoxide was added, exhibited a carbon monoxide 
difference spectrum with a very strong absorption band maximum at 450 nm. Six 
years later this pigment was identified as a protein containing heme (Figure 1) and was 
termed, cytochrome P450.
Figure 1 P450 cytochrome with inset of heme and camphor substrate (picture
reproduced from http://www.tem.phv.cam.ac.uk, site accessed June 2002)
Cytochromes P450 are heme-thiolate proteins widely distributed in prokaryotic and 
eukaryotic organisms. The thiolate is derived from a cysteine residue that is part of the 
heme protein. This acts as a tether anchoring the heme to the protein. Evidence for this 
has been obtained from X-ray crystallography.^ The cysteine sulfur ligand (yellow) can 
be seen in Figure 2.
Figure 2 (picture reproduced from http://www.tcm.phv.eam.ac.uk, site accessed 
June 2002)
Cytochromes P450 have been isolated from numerous mammalian tissues (liver, 
kidney, lung, adrenal cortex, and intestine), insects, plants, yeasts and bacteria."^  
Cytochromes P450 exist in a number of forms known as isozymes or isoforms. About 
500 different P450 isozymes have been reported. These are referred to collectively as 
the cytochrome P450 superfamily.
Cytochromes P450 are known to catalyse a range of reactions including hydroxylation 
of saturated alkanes and of arenes, N-, S-, and O- dealkylations, sulfur oxidation, N- 
oxygenation, dehalogenations and epoxidations.^ All of these reactions require the 
oxidising agent O2 as well as a reducing agent, which is either NADH or NADPH.
Because they require both a reducing agent and an oxidising agent, these enzymes are 
called mixed-function oxidases.
These reactions are essential for the body to monooxygenate many endogenous 
substrates, such as fatty acids, which are converted into essential prostaglandins, and 
also a wide range of xenobiotics. The importance of these enzymes in drug 
metabolism, toxicology, carcinogenesis, and fatty acid metabolism has made the 
cytochrome P450 family one of the most widely investigated classes of enzyme.
1.2 Location and physical characteristics of P450
Cytochromes P450 are obtained from two main sources, that is bacteria and the 
membrane of mammalian endoplasmic reticulum. Both sources give rise to P450s, but 
due to the different environments in which the P450 enzymes are produced it is easier 
to extract a pure P450 from bacterial, rather than mammalian sources. This is due to 
the ease with which a gene can be inserted into bacteria. Such a gene will express a 
single isoform of P450. The removal of these single isoforms is possible because the 
bacterial P450s are water soluble and crystallisable. In mammalian species P450s are 
found in most tissues, though the greater proportion is found in the liver where P450 
enzymes are located in the smooth endoplasmic reticulum membrane of hepatocytes. 
In mammalian tissues there tends to be a large number of different P450s present, 
which makes purification rather difficult. X-ray crystallographic data have mainly
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been obtained for bacterial P450s because they are crystallisable, whereas mammalian 
P450s are membrane bound and not crystallisable in their natural form.
The eventual purification and reconstitution of individual mammalian isoforms 
provided evidence for enzyme multiplicity and allowed for the characterisation of 
substrate and product selectivities. Examples of two different P450s are shown below 
(Figure 3).
Figure 3 Examples of two different P450s; on the left mammalian cytochrome 
P450 2C5 and on the right cytochrome P450cam (camphor monooxygenase (pictures 
from http://pdb.ccdc.cam.ac.uk).
In the pictures above, the two P450s have differing proteins surrounding the heme 
unit, which is identical in both. The 3D structure of P450 has been determined using 
three different bacterial P450s and, although the sequence homology for these proteins 
is less than 10 per cent, the overall folding of the proteins is quite similar (Figure 4).^
11
Figure 4 Three dimensional structure of P450bm-3(CYP102). (picture reproduced 
from Cytochrome P450, Kluwer Academic / Plenum Publishers, 2"^  edition, Paul R. 
Ortiz de Montellano (Editor), p i54, 1995)
The proteins exhibit a two-domain structure comprising a |3-sheet-containing domain 
(the ribbon arrows to the left in Eigure 4) and an a-helix-rich domain (the spirals to the 
right in Eigure 4). The dominant element is an a-helix (the I helix) that traverses the 
entire protein (top to bottom in the centre of Figure 4) and participates with three other 
helices (D, E and L) in defining the heme binding region and the substrate oxidation 
site. In addition, there is a depression in the protein that allows close approach (8-10Â) 
of a redox partner (a flavoprotein or an iron-sulfur protein) to the heme group. The 
path of the reductase to the heme is not certain.^
All members of the P450 family show absorption at 450 nm upon formation of the 
reduced P450-carbon monoxide complex. The overall absorption of these enzymes
12
varies from 447 -  452 nm with an absorption maximum at 450 nm, the so called Soret 
peak (Figure 5).
Figure 5
June 2002)
400.0 450.0 
W avelength (nm)
500.0
(picture reproduced from http://www.tcm.phv.cam.ac.uk. site accessed
This peak is due to a electronic transition (Figure 6).
[ t t  , t t * )
Porphyrin 
Orbitals
Figure 6 (Reproduced from Suslick, K. New. J. Chem., 1992, 16, 634)
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This may be explained by Gouterman’s four orbital model (Figure 7).
Figure 7 The highest occupied molecular orbitals (aiu and a2u symmetry) and the 
lowest unoccupied molecular orbital (Cg symmetry) of metalloporphyrins (Reproduced 
from Suslick, K. New. J. Chem., 1992,16, 634).
In this model the four orbitals are porphyrin n and n* orbitals; the two highest 
occupied molecular orbitals (HOMOs) of aiu and a2u symmetry, and the two lowest 
unoccupied molecular orbitals (LUMOs) are of eg symmetry (Figure 7). Two major 
absorbances arise from coupling of the two transitions between the HOMOs and the 
LUMOs (Figure 7). A linear combination of the two transitions occurs with 
reinforcing transition dipoles, resulting in a very intense absorption.
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Further characteristic peaks are found in heme at ~570 nm, though of a less intense 
nature than that of the Soret peak. This is a result of ligand to metal charge transfer 
(LMCT) and d-^d* electronic transitions (Figure 8) in the hemoprotein caused by the 
ligation of the sulfur containing residue to the heme prosthetic group.^’^
Id.dl
7T
[LMCT]
Metal
O rbitals
Porphyrin
O rbitals
(Reproduced from Suslick, K. New. J. Chem., 1992,16, 634)
This was first suggested by Mason, and later the Fe-S stretch was proven by 
Champion^ when a perturbation was observed in the Fe-S stretch frequency after direct 
sulfur and iron isotope substitution. Substrate (and carbon monoxide) free P450 
exhibits a UV Soret absorption maximum at approximately 420 nm. This is associated 
with the low-spin state of Fe^ .^ Spectral,^ NMR^° and crystallographic^^ data indicate 
that a water molecule forms a sixth axial ligand of the Fe^ "*" in the substrate-free form 
(Figure2, the red ligand trans to the thiolate), thus stabilising the low-spin state of the 
iron.
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There are three types of ligand binding, which may be identified by changes in the UV 
spectrum. These are known as type I, type II and reverse type I.
Type I binding is associated with the binding of a molecule that is a substrate for P450 
oxidation (Figure 9). It is identified by a reduction in the Soret absorption band at 420 
nm, and a corresponding increase in a maximum at 390 nm, with an isobestic point at 
407 nm. This is indicative of a change from a low-spin state to a high-spin state of the 
Fe^ "^ . X-ray crystallography of substrate-bound complexes of the enzyme^ shows that 
the iron-ligated water molecule is displaced in these cases, changing the Fe^  ^from a 
six-fold to a five-fold co-ordination state. The iron is also seen to move out o f the 
plane o f the heme.
Figure 9 The active site of camphor bound to P450cam (picture reproduced from 
http://www.tcm.phv.cam.ac.uk, site accessed June 2002).
A type II spectrum is characterised by an increase in the absorption between 425 nm 
and 435 nm and a decrease in the 390 nm maximum with an isobestic point at 
approximately 419 nm.^^  This is correlated with an increase in the low-spin character 
of the Fe^ "^ . This spectral change is associated with the interaction o f inhibitors, which
16
bind directly to the Fe^ % replacing the water molecule as the sixth axial ligand (Figure 
10).^ ’^^ ^
Figure 10 The active site of metyrapone-bound P450cam, an example of an 
inhibitor-bound system. Note that the inhibitor binds directly to the heme replacing the 
water molecule as the sixth axial ligand.
The reverse type I spectrum, not surprisingly, is a ‘mirror image’ of the type I spectral 
change, with an increase in the 420 nm band and a decrease in absorbance at 390 nm. 
This is similar to a type II change, except that there is no shift in the location of the 
maxima. The exact nature of this interaction is not known and it may be that the ligand 
binds to a different site on the enzyme.
Figure 11 displays typical type I and type II absorption traces. These are difference 
spectra; that is the difference in absorption between that of a reference sample and that 
of the sample to be recorded. This accounts for the occurrence of negative absorption 
in the spectrum due to lower absorption at specific wavelengths compared to that of 
the reference.
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Figure 11 (picture reproduced from http://www.tcm.phv.cam.ac.uk, site accessed 
June 2002)
1.3 Nomenclature
There are several distinct types o f redox proteins and enzymes, which have historically 
been termed cytochromes. It appears that the only feature in common between these is 
the possession of a heme group, with the primary, secondary and tertiary features 
being quite different. Cytochrome P450 may be regarded as a heme-thiolate protein. 
Other cytochromes tend to possess at least one histidine residue that ligates to the 
heme iron. Thus, the P450 family can be separated into a unique group of its own with 
corresponding nomenclature.
There is a systematie naming of P450s that has been in place since 1989. The symbol 
GYP is used as an abbreviation for cytochrome P450, which is italicised when 
referring to the gene. An alphanumeric designation is used in the naming of P450 
families, subfamilies and individual proteins. For example, CYP2A1 implies
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cytochrome P450 family 2, subfamily A, protein 1. The nomenclature of new P450 
sequences is determined by their similarity to others previously assigned. There is a 
general rule that assignment of a P450 gene requires a <40% identity between a P450 
in one family and that in another family, and that there is a >40% identity between 
subfamilies of a given P450 family. Table 1 shows a summary of P450 superfamily 
nomenclature.
Table 1 Cytochromes P450 and the species they metabolise
CYP Functionality or species
1-3 Metabolism of foreign compounds
4 Metabolism of long chain fatty acids
5 Thromboxane biosynthesis
6 Insect forms
7 Steroid forms
8 Prostacyclin biosynthesis
9 Insect forms
10 Mollusc forms
11-21 Steroid biosynthesis
24 Vitamin D3 metabolism
26 Retinoid metabolism
27 Bile acid biosynthesis
51-70 Fungal forms
71-100 Plant forms
101-140 Bacterial forms
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1.4 Catalytic cycle of P450
The catalytic cycle of P450 (Scheme 1) has been well researched over the past 30 
years. Even so, this cycle is still not completely understood, and the species in brackets 
have not been fully characterised. Nevertheless, the cycle affords the best model for 
the balancing of electrons and nuclei throughout the oxidation reaction.
SHOH:SO]
SOH
OH
»SH
ISHSH
Scheme 1
The first steps of the catalytic cycle, involving substrate binding, electron transfer, and 
dioxygen association, have been fairly well characterised because these intermediates 
are fairly stable and have a UV/visible spectrum that makes them amenable to 
investigation.
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Beginning the catalysis at (1), with the substrate-free, oxidised (Fe ‘^^ ) state, this has a 
redox potential of about -300 mV with the heme iron in the low-spin six co-ordinated 
form. Solution X-ray of the substrate-free cytochrome has unambiguously documented 
water or OH as the sixth ligand. In (2) the binding of the substrate (SH) results in 
displacement of water from the active site and a change in the redox potential from 
-300 mV to about -170 mV. Hence substrate-bound P450 becomes more easily 
reduced. Substrate binding to P450 causes a spectral change related to spin state 
conversion of the heme iron. This is caused when (1), a low-spin six co-ordinate heme 
iron, loses water upon addition of substrate to form a five co-ordinate high-spin state, 
with the iron out-of-plane of the porphyrin ling.^ '^^ ^
An electron transfer then occurs to reduce ferric heme to ferrous heme. This electron is 
made available from NADH or NADPH. However, NAD(P)H prefers to donate two 
electrons. Therefore these electrons are transferred to an electron transport protein, 
then to a co-enzyme which can transfer single electrons. This reduction of (2) to (3) 
results in the heme having a higher affinity for dioxygen to bind as the sixth axial 
ligand,^  ^to form (4). Oxygen binding forms a low-spin heme peroxy radical or ferric 
superoxide species (4). This has been characterised by Sligar^ .^ If (4) is reduced 
further by electron transfer, then formation of (5) can occur, which, upon addition of 
two protons and loss of water, results in (6), a high valent iron-oxo species. This 
species, drawn in Scheme 2 as (10) can also be described by the more stable 
resonance form (9)^^  or the other forms shown in Scheme 2.
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(12)
•  +
SH
(11)
(10)
SH
SH
Scheme 2
The abstraction of an H atom from the substrate by this species gives the formation of
(7) and a substrate radical species. This collapses via oxygen rebound to form (8). It is 
not known if any of the bracketed species exist and it is possible that (5), (6), (7) may 
proceed through a concerted mechanism up to formation of the ferric alcohol complex
(8). This oxygenated substrate may then be released to regenerate the initial state of 
P450.
1.5 Enzymology of cytochrome P450 reductase
Mammalian NADPH-cytochrome P450 reductase (CPR) was first identified by 
Horecker in 1950.^® These studies identified it as a flavoprotein (a group of enzymes 
containing flavin bound to protein and acting as dehydrogenation catalysts in 
biological reactions), although it was not recognised until the studies of Lyanagi and
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Mason^  ^ in 1973 that the enzyme contains both FAD (a coenzyme of some 
fiavoproteins) and FMN (a yellow crystalline phosphoric ester of riboflavin that is a 
coenzyme of several flavoprotein enzymes) in equal proportions. The role of the 
flavins in electron flow through the enzyme was elucidated in a series of studies from 
Coon/^ that were based on the redox mid-point potentials determined by Lyanagi et 
al.^  ^These studies established that FAD is the electron acceptor flavin from NADPH 
and that FMN is the electron donor to acceptor proteins such as the cytochromes 
(Scheme 3).
NADPH
electron flow 
- FAD ----- FMN Cytochrome P450
Scheme 3
Under physiological conditions the enzyme was proposed to cycle between 1- and 3- 
electron reduced states as shown below (Scheme 4):
NADPH P450red P450red
FMNH ( ^  FMNH FMNH,. FMNH ^  FMNHo FMNH
FAD A FADH2 FADH ( FADH FAD C FAD
r
NADP+
le‘ 3e"
P450qx
3e" 2e' 2e"
P450ox
le'
Scheme 4
1.6 Biomimetic oxidations catalysed by transition metal 
complexes
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Metalloenzymes catalyse a host of biological oxidation reactions that are crucial to life 
processes. Cytochrome P450 is an oxidoreductase that activates molecular oxygen 
(O2) and incorporates one of the oxygen atoms into a wide variety of biological 
substrates, with concurrent two-electron reduction of the other oxygen atom to water.  ^
These oxygenation reactions metabolise steroids and prostaglandins, effect drug and 
xenobiotic detoxification and can bring about carcinogen activation. The active site of 
this enzyme has been determined from X-ray crystal structures  ^and has been shown to 
be extraordinarily simple, with an iron protoporphyrin IX (heme) (Figure 12) buried 
deep in a protein scaffold.
t = N
Cys
COOH COOH
Figure 12
The heme has a cysteinate thiolate as the fifth ligand and an open co-ordination site to 
bind and activate molecular oxygen.
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Small, synthetic active-site analogs are an invaluable tool in the study of 
metalloproteins. These so-called “enzyme models” can be used to obtain information 
about fundamental aspects of structure, reactivity and mechanism and are suitable for 
spectroscopic study of putative reactive intermediates/"^ Enzyme models can provide 
insights into aspects that are not so easily attainable from the study of the protein 
itself. The advantages of enzyme models are, first of all, that they are readily available 
in large quantities, whereas the natural systems are often difficult to isolate. Secondly, 
the study of mechanism and intermediates in model compounds can provide a basis for 
postulating biological reaction pathways and possible intermediates, or can be used to 
validate existing proposals. Finally, through systematic ligand variation information 
about structural and electronic aspects governing the reactivity can be obtained. 
Moreover, this may lead to new generations of biomimetic catalysts with improved 
selectivity, reactivity and stability.
Studies using metalloporphyrins as models for cytochrome P450 have afforded 
important insights into the nature of these enzymatic processes. The first synthetic 
system used to model the chemistry of cytochrome P450 was Fe(III)TPP(Cl) using 
iodosylbenzene as the oxidant. This was used to carry out epoxidation of olefins and 
the hydroxylation of hydrocarbons.^^ Many other metalloporphyrin-catalysed studies 
have been carried since that time. The first systems to be used employed 
metalloporphyrins containing metals such as iron, manganese, cobalt and chromium, 
and used oxygen atom donors such as peroxides, PhIO and NaOCl. Using these, it has 
been possible to generate species that give the same reactivity as in the O2 system, a 
pathway known as the “peroxide shunt” (Scheme 5).^ ^
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Porph-Fe'"
ROOM
Porph—Fe
,0—R
Peroxide shunt
Porph—Fe
Scheme 5
The following (Table 2) show a selection of metalloporphyrins used in model studies.
Table 2 Different metalloporphyrins used in model studies
Metalloporphyrins Substituent (R) 
o m P
(TPP)Fe^^(Cl) H H H
(TPP)Cr’*(Cl) H H H
(TPP)Mn^^(Cl) H H H
(F2oTPP)Co’^(C1) F F F
(CI:TPP)Fe^XCI) Cl H H
(ClgTPP)Mn^^(CI) Cl H H
Much effort has been taken to improve the catalytic reactivity of iron porphyrin 
complexes^^’^ .^ An important finding for this was that the introduction of electron 
withdrawing substituents (eg F) into the phenyl groups of porphyrin ligands enhanced 
the reactivity of the iron porphyrins greatly and diminished the oxidative degradation 
of the porphyrin ligands dramatically^^'^\ Even more effective iron porphyrin catalysts 
were achieved when the porphyrin ring was fully halogenated^^. These highly
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electron-deficient iron porphyrins turned out to be remarkable oxidation catalysts with 
fast reaction rates and high product yields.
1.6.1 The metalloporphyrin-iodosylbenzene system
Organoiodine(in) species have unique properties and structures and are commonly 
described as hypervalent, owing to the increased valency of the iodine atom^ .^ 
Iodosylbenzene (PhIO) is, perhaps, the most widely known and utilised 
organoiodine(in) reagent. Not only does this readily prepared reagent serve as a 
starting material for the synthesis of a wide variety of other organoiodine(III) species, 
but it also acts as an effective oxidant for many substrates^ "^ '^ .^ Its oxidising ability is 
greatly extended when it is used in conjunction with appropriate transition metal 
catalysts, and it also has found extensive application as a primary oxo source for 
hydrocarbon oxidations and biomimetic studies^ ’^^ .^ Groves^  ^has shown that oxidation 
reactions carried out by synthetic porphyrins in the presence of iodosylbenzene have 
similar mechanistic features to those of P450. There are two proposed mechanisms for 
the hydroxylation of hydrocarbons:
(1) oxygen rebound from the iodosylbenzene to the substrate via an iron-oxo 
intermediate (13), and
(2) oxygen activation by the co-ordination of iodine to the porphyrin (14).^^
Scheme 6
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The exact mechanism that is followed is still under investigation, but is most likely 
that of oxygen rebound?^ For the hydroxylation of hydrocarbons this gives a
mechanism as shown below (Scheme 7).28
R OH R H
H R
.4+
Scheme 7
1.6.2 The metalloporphyrin-alkylhydroperoxide system
Studies of reactions utilising metalloporphyrins with iodosylbenzene and peracids 
have provided important insight into the nature of oxidations occurring from 
hemoproteins such as P450, peroxidases and catalase. Although PhIO is a useful 
mechanistic tool, it is of limited biological relevance since it doesn’t occur in plant or 
animal metabolism. In contrast, hydrogen peroxide and fatty acid hydroperoxides are 
widely distributed in the plant and animal kingdom, and support a variety of 
oxidations by heme proteins. This makes the study of alkylhydroperoxides with 
metalloporphyrin systems an interesting, and relevant, area of research.
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Similar to the 1=0 bond in iodosylbenzene, the 0 - 0  bond in hydroperoxides is cleaved 
heterolytically by the iron porphyrin complex resulting in a high valent iron(TV)-oxo 
porphyrin cation radical intermediate (0=Fe^-porph^ ). Alternatively, unlike 
iodosylbenzene, homolytic cleavage of the 0 - 0  bond can also form 0=Fe^-porph^. 
Thus, the two proposed routes for 0 - 0  bond cleavage with hydroperoxides and 
metalloporphyrins are,
(1) heterolytic cleavage to form an 0=Fe^-porph^' complex (Scheme 8, pathway A)
(2) homolytic cleavage to form an 0=Fe^-porph complex (Scheme 8, pathway B)
It is important to consider which of these routes is followed, because if the 0=Fe^- 
porph complex is formed hydrogen abstraction from the substrate is not possible, but 
in its formation an alkoxyl radical species is formed in the homolytic breakdown of the 
hydroperoxide. The alkoxyl radical is able to abstract a hydrogen atom from the 
substrate."^ '^"^  ^However, the 0=Fe^-porph^' complex is able to abstract a hydrogen 
atom from the substrate forming a Fe^-OH species that hydroxylates the carbon 
centred radical formed.
29
— Fe'"-Porph + ROOM
Heterolysis
ROM + — Fe"^~PorpT) 
I
olefin
High yield of epoxide formation 
with a retention of stereospecificity
— Fe'"-Porph 
(15)
ROOH Î00
I
rcT + O2
Homoiysis
OH
— Fe'^-Porph + OR 
(16)
oiefin
Low yieid of epoxide formation 
or a loss of stereospecificity
Scheme 8
Traylor has proposed that heterolytic cleavage of the 0 - 0  bond in (15) occurs to give 
the formation of (17) as the reactive species in olefin epoxidation.^^’'^  ^'^  ^This has been 
shown in protic alcohol solvents such as MeOH, with the protic solvents being
proposed acid catalysts"^ .^
Bruice in contrast, has provided evidence that the initial step of the 0 - 0  bond cleavage 
of (15) in aqueous or aprotic solvents is homolytic, resulting in the formation of a 
ferryl-oxo complex Several other groups also support the occurrence of 0 - 0
bond homolysis in aqueous and aprotic solvents. Traylor has proposed that product 
distributions may be accounted for by initial heterolytic cleavage of the 0 - 0  bond, 
with a subsequent side reaction between (17) and ROOH taking place at a high rate
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(Scheme 8, Pathway A followed by pathway C). This would result in the expected 
product distribution from 0 - 0  bond cleavage.
Further studies by Nam have shown that the hydroperoxide bond is cleaved both 
homolytically and heterolytically in aqueous solution and in protic solvents. The ratio 
of each depends upon conditions, such as:
(1) the electronic nature of the iron porphyrin complexes, where iron porphyrins 
containing electron deficient porphyrin ligands result in an increase in heterolytic 
cleavage, and electron rich porphyrin ligands give an increase in homolytic 
cleavage, and
(2) the alkyl substituent of the hydroperoxide, with electron-donating rg/Y-alkyl groups 
tending to give 0 - 0  bond homolysis and electron withdrawing groups, such as 
acyl, facilitating 0 - 0  bond heterolysis.^ '^^^
2 Reactions catalysed by P450
2.1 Aliphatic hydroxylation
Hydroxylation of unactivated alkanes was initially thought to undergo a concerted 
insertion process (Scheme 9).
H--R
Scheme 9
This mechanism was proposed because of low deuterium isotope effects (kn/ko <2)^  ^
(Scheme 10).
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Scheme 10
However these results were shown to be erroneous by Hjelmeland and Groves, 
who showed that the isotope effect on, for example, norbomane hydroxylation was 
much larger (kn/ko >11). These differences arise from the fact that the earlier studies 
utilised intermolecular isotope effects. These are obtained by comparing rate 
differences using unlabelled versus deuterium labelled substrates. However, if the C-H 
bond is not involved in the primary rate-determining step then the difference in rates 
between the isotopically labelled substrates will be small. The studies of Hjelmeland 
and Groves were carried out using a technique that measured the intramolecular 
isotope effect. This involves hydroxylation of a substrate containing two identical and 
symmetrical sites, one of which incorporates deuterium (Scheme 11).
X
—  r i
X
X A . XH H H OH H H
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Now the extent of C-H vs. C-D bond cleavage may be determined more accurately. 
The large deuterium isotope effect observed suggests that C-H bond cleavage is a 
chemically important step that is masked by other processes. The size of the isotope
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effect suggests a two-step mechanism, either involving a radical pathway or via the 
formation of a carbocation.
Evidence for a two-step mechanism can be observed from the stereochemical 
scrambling of deuterated substrates incubated with P450. An appropriate example of 
this is with ejco-2,3,5,6-tetradeuteronorbomane incubated with CYP2B4 (Scheme 
11).^^  In this reaction four norbomanols are produced. This shows that the reaction 
does not proceed with retention of configuration and so supports a two step 
mechanism
OH OH
P450
OH OH
Scheme 12
If the reaction takes place via a radical mechanism, then abstraction of a hydrogen 
atom from the substrate will give a heme-bound hydroxyl radical and a carbon-centred 
radical (see Scheme 13). These two may then combine to form the hydroxylated 
product (18) a process termed oxygen rebound.^^
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Scheme 13
Evidence to support a pathway involving formation of the carbon-centred radical 
comes from the use of ultrafast radical clock probes (Scheme 14)^ .^ In this case a 
strained cyclopropyl compound, 1 -methyl-2-phenycyclopropane (21), whose
radical rearranges at the remarkable rate of 3 x 10“ s '\  was oxidised using P450 and 
three oxidation products (23), (24) and (26) were observed (Scheme 14). Compound 
(23), the product of simple hydroxylation is formed via pathway A, through the 
formation of the cyclopropylcarbinyl radical intermediate (22). The latter can either 
undergo oxygen rebound to form (23) or rearrangement followed by oxygen rebound 
to form (26). Pathway B accounts for the third product. Use of the perdeuteriomethyl 
analogue leads to an increase in the oxidation at the phenyl ring. This process is called 
metabolic switching, that is deuteration at one site changes the partition between two 
metabolic pathways due to the isotope effect on C-H bond cleavage at the first site.
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Scheme 15 shows the most likely mechanism with oxygen rebound for the alkane 
oxygenation by heme-dependent monooxygenases.
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Scheme 15
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2.2 Alkene epoxidation
Alkenes are oxidised by cytochrome P450 to epoxides. This can be explained by a 
radical mechanism (Scheme 16) similar to that for alkane hydroxylation. This 
mechanism shows radical addition to the 7C-bond of the alkene to give (27). This 
collapses to the epoxide (28) leaving a high-spin ferric heme.
N— -N
(28)
(27)
Scheme 16
This simple picture of alkene epoxidation may not tell the true story. Spectroscopic 
data from model studies have indicated that an intermediate is formed on the way to 
epoxide formation (Scheme 17). Groves has suggested either a 7i-complex (29) or a 
oxametallocycle (30) for this intermediate.^^
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N— -N
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Scheme 17
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Bruice, alternatively, has suggested epoxidation may involve a charge transfer 
complex between the iron-oxo species and the alkene followed by concerted 
epoxidation/ '^^^
With the epoxidation of terminal olefins it has been found that N-alkylation of the 
prosthetic heme group can occur^ ®. It has also been observed, using E-l-deutero-1- 
octene, that:
(1) olefin stereochemistry is preserved, i.e. the oxygen and pyrrole-N add to the same 
face of the olefin, and
(2) the oxygen atom is delivered to the re face of the double bond^\ This suggests a 
degree of stereochemical control in the reactions.
From the above results the following mechanism has been postulated (Scheme 18).
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2.3 Arene hydroxylation
Aromatic oxidation usually involves the introduction of a hydroxyl group (Scheme 
19).
OH
P450
Scheme 19
This commonly involves epoxidation of the aromatic ring followed by epoxide ring 
opening, migration of a hydride to the carbocation generated, and tautomérisation of 
the ketone product formed, an overall process called the NIH shift. The NIH shift is 
evidenced by appropriate deuterium labelling (Scheme 20).
NIH Shift
R - r -R i-
OH
Scheme 20
The isolation of naphthalene 1,2-oxide (32) (Scheme 21) after P450 oxidation of 
naphthalene (31) is evidence in support of this pathway.
P450
(31) (32)
Scheme 21
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Deuterium substitution does not markedly affect the hydroxylation rate because the 
hydrogen shift occurs after the rate-limiting enzymatic epoxidation step. 
Decomposition of either [1-^H] or [2-^H] naphthalene 1,2-oxide yields 2-naphthol (34) 
having identical isotopic composition (Scheme 22), indicating a common intermediate 
(33) that originates from the two arene oxides.
Scheme 22
Formation of (33) could come from two pathways (Scheme 23), one concerted 
(pathway A) the other stepwise (pathway B).
Scheme 23
Two pieces of evidence rule out the concerted pathway:
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(1) there is no deuterium isotope effect observed,and
(2) with various substituted arene oxides a Hammett plot shows a large negative p 
value, indicating that positive charge develops in the transition state.^^
Other evidence, however, suggests that the arene oxide is not produced (but may be 
formed by an alternative pathway). The most likely route (Scheme 24) for the 
formation of phenols not involving the formation of arene oxides, involves oxidation 
of the Tt-system of the substrate to give a radical cation (36). The involvement of a 
singe electron transfer step is supported by a Hammett relationship between the rates 
of para-hydroxylation of monohalogenated benzene by CPY3B1 and the values 
(which correlate to the 'Em values for benzene) of the substituents.^"  ^It should be noted 
however that oxidation of cyclopropylbenzene by cytochrome P450 gives 1- 
phenylcyclopropanol and phenol metabolites without detection of ring-opened 
products (Scheme 24).^  ^This suggests no electron abstraction from the aromatic ring.
•OH
F e— OH
(35)
/ /  ^  Ring-opened 
M etabolites
F e = 0 (36)
F e —O'
OH
Scheme 24
For the moment, evidence for any mechanism is weak, the following (Scheme 25) 
gives an outline of the most likely routes.
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2.4 Heteroatom oxidation
Sulfur-, phosphorus- and nitrogen- containing compounds may undergo oxidation to 
the corresponding S, P, or N-oxidcs. This happens particularly when there are no a- 
hydrogens adjacent to the heteroatom. The mechanism is believed to involve electron 
transfer followed by oxygen rebound (Scheme 26).
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Ethers on the other hand do not undergo oxygenation, since the oxygen atom has a 
much higher oxidation potential than the corresponding sulfur or phosphorus 
analogues^ '^^ .^ The cytochrome P450 catalysed oxidation of alkylamines can result in 
N-oxygenation or N-dealkylation. The formation of N-oxides is not common but has 
been observed; N-dealkylation is the more common process. N-Oxide formation 
becomes the major pathway when the nitrogen has no a-hydrogen atoms available or 
the a-hydrogen atoms are inaccessible for abstraction (for example in strained cyclic 
systems).^ ’^^ ^
2.5 O-Dealkylation: ethers and esters
P450s are known to cleave the C-0 bond of ethers through a mechanism that involves 
C-hydroxylation^^ to form a hemiacetal (Scheme 27).
Scheme 27
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72A large deuterium isotope effect of ca. 8 is observed, indicative of a hydrogen atom 
abstraction process.
Esters undergo a similar cleavage (Scheme 28). As esters are even more electron 
deficient than ethers they also will favour a hydrogen atom abstraction pathway, a
deuterium isotope effect of ca. 8 confirming this.73
(Fe''=0)^^ (Fe-0H)3+
V y  ■
R OH
Scheme 28
2.6 N-Dealkylation: amines, amides and their differences
Like ethers and esters, amines and amides undergo P450 catalysed dealkylation 
(Scheme 29).
OH
\  P450 \  I
N CHgR  CHR
Scheme 29
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In contrast to amides, amine P450-dependent metabolism has received extensive 
mechanistic attention. Both compounds generate N-dealkylation products through the 
formation of either a carbinolamine or carbinolamide, respectively. Because of these 
similarities it would be tempting to suggest that both follow the same metabolic 
pathway, but there are important physical and chemical properties to consider (Scheme 
30).
Amine Amide
Scheme 30
Aliphatic amines have a non-bonding electron pair of electrons in an sp^  orbital; these 
electrons are readily available for bonding and generally have low ionisation potentials 
(~7.8eV). This is not the case for amides, where the corresponding electron pair 
occupies a delocalised 7r-orbital that involves the carbonyl group; consequently these 
electrons are much less available and the ionisation potentials of amides (~9.1eV) are 
consequentially higher than those of amines.
Substituted amines bearing a-hydrogen atoms readily undergo cytochrome P450- 
catalysed N-dealkylation by a mechanism that is initiated by single electron transfer 
(Scheme 31).
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From the so-formed amine radical cation proton abstraction can take place to afford a 
carbon-centred radical. Oxygen rebound at this stage gives a carbinolamine (37) that 
can readily decompose to the N-dealkylated amine (38) and corresponding aldehyde 
(39).
Several lines of evidence support this mechanism:
• kinetic deuterium isotope effects for alkylamine dealkylation are small (1.3-3.0)^\ 
in contrast to 0 -dealkylation and carbon hydroxylation^^’^ ^
• cyclopropylamines are suicide substrates for P450 (Scheme 32).
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Amides do not readily undergo one-electron oxidation but do exhibit N-dealkylation 
reactions. Scheme 33 outlines the possible routes of amide oxidation, They give 
relatively large kinetic deuterium isotope effects (kn/ko = 4-7).^  ^ Moreover, P450- 
mediated metabolism of N-cyclopropylamides does not lead to suicide activation of 
the enzyme, even though N-dealkylation occurs.^  ^Taken together, these results 
suggest that N-dealkylation of amides involves direct hydrogen atom abstraction (path
a) rather than nitrogen radical cation formation (path b. Scheme 33). This difference in 
mechanism must be related to the higher ionisation potential of amides as compared 
with amines.
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2.7 Amide and amide-like solvents DMF, HMPA and 
DMPU
DMF, HMPA and DMPU (Scheme 34) are dipolar aprotic solvents that are used in 
large quantities both in industry and, to a lesser extent, research laboratories. 
Unfortunately, both DMF and HMPA have toxic properties, which has lead to the 
increasing use of the non-mutagenic DMPU as a ‘safe’ alternative. DMF and HMPA 
are pro-carcinogens, that is they require activation via oxidative metabolism to induce 
carcinogenic activity. During this metabolism, cytochrome P450 enzymes catalyse the 
removal of a methyl group by oxidative dealkylation. Toxicity is presumed to arise 
from the reactive intermediates formed during metabolism. One candidate for such an 
intermediate is the amide derived carbon-centred radical mentioned previously
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(Section 2.6) and which has recently been intercepted using an intramolecular radical 
probe. However, all three dipolar aprotic solvents can potentially afford such an 
intermediate so the difference between DMPU on the one hand and DMF/HMPA on 
the other remains to be established.
oM I? IVIe P Me
Me V
N,N-dimethylformamide 1,3-dimelhyl-3,4,5,6,-tetrahydro-2(1H)-pyrimidone Hexamethylphosphoramide
DMF DMPU HMPA
Scheme 34
Dimethylformamide
Dimethylformamide is a known toxic agent that can lead to gastric irritation, 
pancreatic disorders,^  ^carcinogenesis,^^ and hepatotoxicity^^ and it is also known to 
affect skeletal muscle.^  ^Microsomal oxidation of DMF has been shown to produce N- 
methylformamide NMF, probably via the route shown (Scheme 35).
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Recent studies have shown that NMF and DMF themselves are probably not the cause 
of this toxicity and that metabolites involving glutathione have adverse effects.^ "^  
Indeed, méthylation of hemoglobin (a common process) increases 100 fold in the 
presence of DMF.^  ^Although formaldehyde, a known carcinogen, is released during 
metabolism of DMF, this alone does not account for the degree of toxicity in DMF. 
The metabolic route shown (Scheme 35) has been postulated in the light of the 
metabolites i so la te d .S e v e ra l  approaches have been taken to trap the possible
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carbon-centred radical and iminium ion intermediates (Scheme 36) that form during 
amide metabolism.
X  ^ "«° . or Déméthylation XH N
0 1
Scheme 36
One involves the use of an N-(3-butynyl) substituent as a radical trap (Scheme 37). 
Metabolism of N-(3-butynyl)-N-methylformamide (40) can potentially afford six 
products. In fact only A, B, and C were isolated.The formation of B demonstrates 
that radical formation occurs at the a-carbon (Scheme 37).
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Me(40) MeMe
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Scheme 37
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Direct observation of radical formation by ESR is difficult because of the aqueous 
medium and because the lifetime of radicals tends to be too small to measure. 
However, radical trapping by N-re/t-butyl-a-phenylnitrone yielded a stable nitroxyl 
radical (41) that has been observed^  ^(Scheme 38).
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The above results indicate that DMF undergoes déméthylation via a carbon-centred 
radical. Formation of this carbon-centred radical may partly explain the toxicity 
associated with DMF. For example, there is evidence for the formation of a heme 
adduct with DMF that is metabolism dependent.^  ^One explanation is that heme traps 
the carbon centred radical formed during metabolism. Certainly, there is a metabolism- 
dependent destruction of heme.^^
HMPA
Hexamethylphosphoramide (HMPA) is a dipolar aprotic solvent possessing unique 
properties. It has been widely used in small-scale organic and organometallic 
syntheses in laboratories and for industrial processes such as UV inhibition in PVC 
and as a de-icing additive for jet fuels.^  ^Unfortunately, it has been extensively 
reported that HMPA has severe toxicological effects on living organisms, giving side-
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effects such as such as kidney disease, severe bronchiectasis, and bronchopneumonia, 
with squamous metaplasia and fibrosis in the lungs in rats.^  ^Its mutagenic effects have 
been studied in both rats and house flies. The worst of these are located primarily in 
the nasal mucosa, and it is most harmful by inhalation.^^’^ ® Indeed HMPA is 
metabolised by P450 faster in nasal mucosa than in liver or lung. This implies tissue 
specific metabolism.
HMPA is known to undergo oxidative déméthylation.^^ Given that the product of 
déméthylation, pentamethylphosphoramide, is non-toxic, toxicity may be presumed to 
arise from an intermediate in the metabolic pathway. Several studies have attempted to 
establish the route of metabolism of HMPA, in order to better understand its toxicity. 
Metabolites so-far isolated^ '^^  ^are: pentamethylphosphoramide (PMPA) (42), 
N,N,N',N"-tetramethylphosphoramide (TetraMPA) (43), N,N',N"- 
trimethylphosphoramide (TriMPA) (44), N-formylpentamethylphosphoramide 
(FPMPA) (45), N-formyl-N,N,N',N"-tetramethylphosphoramide (FTetraMPA) (46) 
and formaldehyde (Scheme 39).
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Scheme 39
Metabolism occurs by an oxidative mechanism;^^ in the absence of O2, complete 
inhibition of PMPA formation is observed.^^
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Like DMF, metabolism of HMPA can occur primarily via two routes: oxidation at the 
N atom, or H-atom abstraction from the a-carbon. Ionisation potentials are 
inconclusive since the ionisation potential for HMPA (8.1 eV)^  ^is between that of 
amide (9.11 eV for DMF)^  ^and amine (7.82 eV for methylamine).^®  ^However, 
oxidation at the N atom is unlikely for following reasons:
a) no déméthylation is apparent upon addition of hydrogen peroxide^ "^  or upon 
treatment with peracid^^
b) inhibition by N,N-dimethylbenzylamine of FAD-containing dimethylaniline 
oxidase (an enzyme capable of N-oxidation) leads to an increase (rather than an 
expected decrease) in HMPA mutagenicity^®^
c) the putative N-oxide rearranges to N-((bis(dimethylamino)- 
phosphinyl)oxy)dimethylamine®^ (47), which is non-toxic (Scheme 40).
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The above imply that metabolism probably proceeds via H-atom abstraction, leading 
to hydroxylation of the methyl group and subsequent dealkylation. This is supported 
by:
(a) a study which gives lower than expected amounts of recovered (impling 
deformylation or absorption into body tissue)^
(b) isolation of formamide derivatives "^^
(c) isolation of formaldehyde^®^
\95
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(d) stepwise formation (supported by isolation) of main metabolites PMPA/
TetraMPA/ TriMPA. If PMPA is used instead of HMPA formation of FTetraMPA 
and FPMPA (Scheme 41) has also been observed. This would imply that 
appropriate formylation is involved at each stage, along with analogous methylol 
intermediate.
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Scheme 41
Hence the following mechanistic route is postulated (Scheme 42). 101
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DMPU
Surprisingly, given its recommended use in place of DMF and HMPA,^®  ^very little 
data exist regarding the metabolism and toxicity of DMPU. The data available reveal it 
to have an acute toxicity a little higher than that of HMPA, but there is no evidence for
55
mutagenic or chromosome damaging activity/^^ DMPU is a cyclic urea (48), but may 
be thought of as being very much like an amide (49). (Scheme 43)
Cyclic Urea
(48)
o
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It can be seen that both urea and amide have a nitrogen atom next to a carbonyl group 
but in the urea there is an extra nitrogen atom involved in bonding to the carbonyl. As 
might be expected, therefore, ureas and amides have similar ionisation potentials, but 
of the two the urea is the lower (urea ~ 8.4-8.7eV and amide ~ 8.7-9. leV). 
Consequently, ureas may follow similar oxidative mechanisms to those of the amides. 
An important point to be considered is the site of attack; this is an issue since the 
DMPU is cyclic and so may be attacked at an a-carbon atom in the ring or at the N- 
methyl position. With N-methylpyrrolidinone it has been shown that chemical 
oxidation occurs only on the ring^ ^^  but that P450 oxidation involves N-demethylation 
as well. Remarkably, there are as yet no published studies of the metabolism or 
chemical oxidation of DMPU. Scheme 44 gives the possible routes of metabolism.
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Scope of thesis
It seems remarkable that although DMPU is recommended as a safe alternative for 
HMPA little data is available. In fact there have been no 
• biomimetic studies
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• metabolic pathways published
• toxicology studies
There have been no studies attempting to establish the metabolic intermediates. It was 
thought that by using the same strategies as that applied for DMF, it would be possible 
to determine whether a C-centred radical intermediate is formed from DMPU and 
HMPA in their oxidation.
It is possible to determine the kinetic deuterium isotope effect for the oxidation, with 
the use of deuterated HMPA. This will give an indication of whether the mechanism of 
P450 mediated N-dealkylation proceeds via an initial one electron abstraction like that 
of amines (small deuterium isotope effect)^^’^ ’^^  ^or via hydrogen abstraction (large 
deuterium isotope effect) leading to either a carbon centred radical or an iminium 
ion.^  ^If déméthylation of HMPA occurs via hydrogen abstraction as expected then a 
carbon centred radical or an iminium ion could be formed. This thesis aims to 
determine this effect for HMPA using model studies, which will give further evidence 
as to whether N-demethylation is undergone via a C-centred radical.
3 Discussion
3.1 Analytical Techniques
In the introduction, oxidation of amide solvents is discussed. A suitable analytical 
technique must be developed to determine the products and allow quantitative 
analysis. Literature reports on the product study of microsomal dealkylation of HMPA
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suggested gas chromatography (GC) might be a suitable technique, these reports also 
show that PMPA and FPMPA are formed under microsomal oxidation. Hence it was 
thought these would be the most probable oxidative products produced under model 
studies (using TPPFeCl/ *BuOOH) of HMPA. Following a procedure already used in 
the analysis of N,N-dimethylbenzamide^°^ it was hoped that a similar system could be 
employed for HMPA (Scheme 45).
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In the benzamide system it has been shown that the formyl derivative produced is 
unstable. To determine accurately the quantity of oxidised products formed, the formyl 
product was treated with sodium hydroxide to form N-methylbenzamide (50). It was 
decided that this methodology should also be applied to the HMPA system (Scheme 
45, pathway ii). To develop a suitable analytical system, standard solutions of HMPA 
and PMPA were analysed by GC. These test experiments showed that HMPA and 
PMPA have similar GC retention times (Figure 13).
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Figure 13 GC trace of HMPA and PMPA standards
Although this appears to have good separation, this posed a problem for the analysis of 
reaction mixtures where only 1-5 per cent of HMPA is oxidised to PMPA. Hence the 
large relative concentration of HMPA present swamped any PMPA produced. By 
using a derivatising agent it was hoped that the retention time of PMPA could be 
increased, thus allowing separation. N-Methyl-N-(rgyf-
butyldimethylsilyl)trifluoroacetamide (MTBSTFA) was chosen since it could be 
demonstrated independently, that 98 per cent conversion to the silylated derivative was 
achieved after 10 min.
Using standards of HMPA and derivatised PMPA separation was indeed achieved, so 
several pilot experiments were carried out in which HMPA under went oxidation ( 
0.001 M TPPFeCl in DCM as catalyst, 0.2 M rgrT-butylhydroperoxide as oxidant with 
0.2 M of HMPA as substrate) with deiivatisation of the PMPA. Unfortunately, after 
several kinetic runs repeat injections appeared to show varying amounts of derivatised 
PMPA present. To test if this was experimental or human error two identical
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experiments were run in tandem. These yielded results that varied by 26 per cent, 
whereas independently we were able to verify that reproducibility was within 5 per 
cent. The possible variables contributing to these differences were examined, viz. the 
deterioration of PMPA in alkaline solution and the loss of phosphoramide during 
methanol removal.
To determine if HMPA decomposed in KOH, a test of the stability of HMPA in KOH 
solution was determined. HMPA was left in a 2M KOH solution overnight after which 
time the solution was analysed by ^^ P and ^H NMR and also by TLC. The results 
proved negative; that is, HMPA was found to be stable to alkaline solutions at room 
temperature.
To examine whether or not the product was being lost upon removal of the methanol 
that had been used to quench the reaction, HMPA in methanol was concentrated under 
reduced pressure. A cold trap (-78 °C) was put in place to collect the evaporated 
materials. Analysis of removed methanol showed HMPA present. Given the similar 
physical properties of HMPA and PMPA, this observation could account for varying 
amounts of PMPA present in the reaction mixtures.
To overcome this need for filtration (due to the salt formed after neutralisation of 
KOH by HCl) and evaporation, the following alternative procedure was employed. An 
aliquot of the reaction mixture was quenched in 100 pi of methanol. This aliquot was 
then treated with a solution of concentrated NH3 in chloroform. This solution was then 
reduced in volume under a flow of nitrogen gas to remove any NH3, the resultant 
solution was made up to 800 pi with diethyl ether and then derivatised using 200pl
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MTBSTFA. Using this methodology the solution could be injected directly onto the 
GC column. However, subsequent independent tests with synthetic FPMPA indicated 
that NH3 does not cause FPMPA to undergo deformylation to PMPA. It would appear 
that FPMPA has much greater stability to base than N-formyl-N-methylbenzamide. 
Because of this, it seemed possible that we could analyse for both the N-formyl and N- 
demethylated products. Even so, despite these improved methods being implemented, 
the problem of variable PMPA concentrations and increased amounts of unknown 
compounds persisted.
An increase/decrease in PMPA may have been due to poor injection technique, though 
this may be discounted since multiple injections of a PMPA standard gave identical 
results within experimental error (±5 per cent). However, it was decided that in order 
to eliminate inaccuracies by injection technique and for an improvement in overall 
accuracy, an internal standard should be employed. For an internal standard to work 
effectively it must have a similar retention time to the compound being studied, and a 
concentration giving similar peak height to that of the compound being studied.
n-Octadecane was chosen because it conformed to these factors (Figure 14).
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Figure 14 GC trace showing derivatised PMPA at 15.06min and internai standard 
n-octadecane at 16.71 min.
However, even with the use of an internal standard, erratic results still occurred.
The same oxidation experiments were carried out on a smaller scale, it was observed 
that the products were being catalytically decomposed on the column, possibly due to 
TPPFeCl build up. To test for this, a sample containing pure HMPA and PMPA was 
analysed by GC using a column which had previously been used to analyse model 
reaction mixtures. A large number of compounds was noted on the chromatogram. 
When the first 5 cm of the column was removed (where any catalyst might be 
absorbed), GC of this pure sample afforded only two peaks. Significantly, after several 
reaction mixtures were subsequently analysed the problem re-emerged. This indicates 
that a build-up of contaminant (probably TPPFeCl) occurs at the head of the column, 
which leads to catalytic decomposition of compounds injected into the system.
63
Attempts to remove the TPPFeCl by filtration and column chromatography were 
unsuccessful. Consequently, the use of GC was discontinued.
Following the failure of GC as an analytical technique, high performance liquid 
chromatography (HPLC) was investigated. Initially, to verify the method and to 
confirm experimental techniques, the known dealkylation of N, N-dimethylbenzamide 
was studied.^  ^Analysis was carried out using a Waters C l8 Symmetry column, 
separation was achieved using a water/acetonitrile (50%/50% v/v) eluent (Figure 15; 
N-methylbenzamide (50) at 5.4 min and dimethylbenzamide at 7.9 min).
Figure 15 HPLC trace showing NMBA at 5.4 min and DMBA at 7.9 min
This compound undergoes reaction according to the pathway shown in Scheme 45. 
Two separate aliquots of reaction mixture A (Scheme 45) were taken at regular 
intervals and quenched in methanol. The latter terminates the reaction thus preventing 
any further oxidation of the benzamide. To one of these aliquots, potassium hydroxide 
was added to convert any unreacted N-formyl-N-methylbenzamide (FNMBA) (51) to 
N-methylbenzamide (NMBA) (50). Both aliquots were then separately analysed by 
HPLC. Results for this can be seen in Figure 16, where increasing amounts of N- 
methylbenzamide (NMBA), are formed as the reaction proceeds. It is also apparent 
that a greater concentration of NMBA is present in the sample treated with hydroxide 
(B) due to conversion of FNMBA to NMBA (Figure 16).
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Biomimetic oxidative dealkylation of DMBA
• Treated 
sample B
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Time min
Figure 16
At this stage a study was performed to compare the relative efficiencies of 
tetraphenylphorphyrin iron (III) chloride and tetraphenylphorphyrin manganese (III) 
chloride for the oxidative dealkylation of DMBA. Using identical substrate 
concentrations and concentrations of oxidants this showed that the manganese catalyst 
was less efficient (Figure 17). For this reason, tetraphenylphorphyrin iron (III) 
chloride, it was chosen for all subsequent experiments.
TPPFe vs TPPMn
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Figure 17
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Unfortunately, when the HPLC system employed for the benzamides was used to 
investigate analogous HMPA reaction mixtures, insufficiently adequate separations 
were obtained (Figure 18, HMPA at 2.3min, PMPA at 2.2min). This proved a problem 
in reaction mixtures where HMPA was in excess and swamped the PMPA signal.
Figure 18 HPLC trace showing HMPA at 2.3 min and PMPA at 2.2 min.
HPLC was re-examined, this time employing a PLRPS (polymeric reverse phase) 
column. This column was found to give the necessary separation between HMPA, 
PMPA and FPMPA. This column is stable to chlorinated solvents, thus a system was 
developed where the reaction mixture was added directly to methanol (to quench the 
reaction) and then injected on to HPLC, removing the need for evaporation of 
chlorinated solvent. Figure 19 shows a reaction mixture of oxidised HMPA, with 
PMPA at 17.57min, FPMPA at 21.69min and HMPA being removed in the end wash.
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Figure 19 HPLC trace showing PMPA at 17.57 min and FPMPA at 21.69 min
3.2 HMPA reactions
By using the above-described analytical techniques, it proved possible to create a 
calibration graph of FPMPA and PMPA (Figure 20). This was used to analyse results 
of the reactions of HMPA without the need to convert FMPMA to PMPA.
FPMPA and PMPA CALIBRATION
4000000
3500000
3000000
2500000
2000000
1500000
1000000
500000
0
0.3 0.4 0.50.2 0.6
■500000
CONCENTRATION mg/ml
■  P M P A  
Q  F P M P A
Figure 20 Calibration chart for PMPA and FPMPA (220 nm, 20pl injection,
Iml/min)
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Using the calibration chart in Figure 20 it is possible to analyse the reaction of HMPA 
with TPPFeCl/BuOOH. Such a profile is shown in Figure 21
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Figure 21 graph showing the effects of adding a second aliquot of ^BuOOH to the 
oxidation system as per section 4.5.3 ([TPPFeCl] = 0.001 M, [^BuOOH] = 0.2 M, 
[HMPA] =0.2 M, DCM 20cm^)
It is clear from this that the reaction tails off markedly after about 150 min. This 
corresponds to 5 per cent of reaction. Since this low conversion was thought to be due 
to the consumption of rgrr-butylhydroperoxide via a side reaction to form ^BuOOH and 
H2O, at 1260 min, a further aliquot of rgrr-butylhydroperoxide (of equal concentration 
to the first) was added. A further burst of reaction can be observed, the extent of which 
corresponds to that of the initial reaction.
Plots such as that shown in Figure 21 but taking a greater number of aliquots in the 
initial 20 min phase of the reaction, were used to examine the initial rate of oxidation. 
The initial rates at varying concentrations of HMPA for the déméthylation of HMPA 
to PMPA and oxidation to FPMPA are shown in Figure 22.
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Figure 22
This gives a pseudo-first-order rate constant of 1.7 x 10  ^ s'^  for the combined PMPA 
and FPMPA, 8.6 x lO'^ s'^  for PMPA and 8.5 x lO'V^ for FPMPA. An analogous 
experiment was carried out using the perdeuterated HMPA analogue ^Hig-HMPA 
(Figure 23).
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This gives a pseudo-first-order rate constant of 1.65 x 10'^  s'^  for combined PMPA and 
FPMPA, 8.5 X 10'^  s'^  for PMPA and 8.0 x 10'^  s'^  for FPMPA. Comparing this value 
with that for HMPA, affords a kinetic deuterium isotope effect, kn/kD, of ca. 10. This 
is a large kinetic deuterium isotope effect, which indicates that the reaction involves 
hydrogen atom transfer in the rate-limiting step.
70
The oxidation of N,N-dimethylbenzamide has been similarly ex a m in ed .T h is  has 
been shown to give a pseudo-first order rate constant of 2.2 x 10’^  s '\ Comparing this 
to that obtained for HMPA this gives a difference in rate of 1.3 fold, the amide being 
the more reactive. This does not take into account statistical factors where the 
benzamide has two methyl groups available for attack whereas HMPA has six. Taking 
these factors into account, the benzamide is more reactive than HMPA by a factor of 4. 
This reactivity difference is presumably due to electronic effects of the P=0 group as 
compared with the C=0 group.
To investigate the mechanism of formation of the demethylated and formyl products 
further, the following possible metabolites (45), (54) were synthesised (Scheme 46).
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When HMPA undergoes alkyl group oxidation, it is possible that en route it could 
form several intermediate compounds. One of the most likely is the alcohol (52). 
Subsequent oxidation of this can yield the formyl compound (45). The formyl 
compound may then undergo deformylation to give the demethylated HMPA 
derivative PMPA (alternatively, PMPA may arise directly from (52) by loss of 
formaldehyde). To account fully for all oxygenated products it was decided to try and 
synthesis the alcohol (52) since it may also have been detectable by HPLC. This was 
attempted using PMPA (42) and a 33 per cent formaldehyde solution. This method has 
been employed to form the corresponding amide derivatives.Unfortunately, it prove 
impossible to isolate the alcohol from the reaction mixture; concentrating the product 
always resulted in an intractable tar. This polymer is not detectable by HPLC. 
Alternatively, the alcohol (52) may react with ^BuOOH in solution or with ^BuOH 
(from ^BuOOH), and so could form either (53) or (54), respectively. It can easily be 
seen how the peroxide (54) may be cleaved to form the corresponding formyl 
compound (45), making this a prospective reaction route. The synthesis of both of 
these substances was attempted according to the two reactions in Scheme 47.
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In route (A), PMPA was treated with chlorotrimethylsilane (TMSCI) and 
paraformaldehyde^^ to form the N-chloromethyl derivative (55). This is a highly 
reactive species with the chloride easily substituted by the nucleophilic ^BuOOH or 
^BuOH. However, with either of these nucleophiles a complex mixture of products was 
obtained and so route (B) was utilised. PMPA was reacted with aqueous formaldehyde 
to form a solution that was hoped to contain the alcohol (52). Reaction was then 
attempted of the solution of crude alcohol with the appropriate nucleophile (either 
^BuOOH or ^BuOH), which is also the solvent for this latter reaction. For ^BuOOH, this 
resulted in a very clean reaction affording (54) in quantitative yield. However, when 
^BuOH was used, addition of trifluoroacetic acid (TFA) was required to catalyse the 
reaction, probably because ^BuOH is a weaker nucleophile than ^BuOOH. However, 
this results in a mixture of products. From the ^H NMR spectrum, the products appear 
to be reversion to PMPA (42), dimérisation (56) and formation of the tert-h\x\.y\ ether 
(53) (Scheme 48).
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(54)
Scheme 48
Purification of this latter compound was attempted by column chromatography, which 
resulted in the labile *BuO group being removed. The acidity of the silica may catalyse 
the removal of the *BuO group. Consequently, chromatography on either a silica 
column pre-washed with NEtg to remove acidic sites, or on a basic alumina column
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were attempted, but even so the compound still decomposed on-column. Thus an 
examination of the chemistry of a crude sample of (53) was required. To do this (53) 
was dissolved in water. Analysis of the reaction mixture after 60 min by NMR 
spectroscopy showed that dimérisation (to 56)and déméthylation (to 42)occurs. Loss 
of ^BuOH indicates that the ^BuOH group is too labile to handle and in any case would 
be removed on column by HPLC. For (54) analysis by ^H NMR at 60 min intervals 
showed that dimérisation and déméthylation also occurs, although it does so at a 
slower rate. Because of the problems in handling these products they were not 
observed on HPLC, with only the decomposition product being observed. This is not a 
problem since it means all oxidised products may be accounted for, but does not allow 
determination of possible ^BuOOH or ^BuOH trapping.
That (54) could be an intermediate in the formation of FPMPA during oxidation of 
HMPA by TPPFeCl/ ^BuOOH comes from subjecting it to the same reaction 
conditions as used for HMPA. This results in the instantaneous and exclusive 
formation of FPMPA. FPMPA itself is stable to the same reaction conditions. This 
observation implies that the formation of PMPA and FPMPA come in HMPA 
oxidation arise separate routes. It is possible that formation of (54) occurs from 
addition of a ^BuOO radical to a carbon-centred radical. It is easily seen how the 
decomposition of (54) would result in the formation of FPMPA (42) (Scheme 49).
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PMPA is likely to arise form the oxidation of HMPA to (52) which may then undergo 
deformylation to (42) (Scheme 50).
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3.3 DMPU reactions
Prior to investigating model reactions of DMPU (57), several of the possible products 
were anticipated and obtained. Scheme 51 shows the most probable products that 
could be formed. These were either synthesised or purchased.
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The following procedures outline the synthesis of the above compounds. 1,3- 
Dimethyldihydropyrimidine-2,4-dione (59) and l-methyldihydropyrimidine-2,4-dione 
(64) were synthesised by the route shown in Scheme 52, which involves initial 
Michael addition of the appropriate urea to acrylic acid.
0
MeHNT'NHMe
> 0
H+, heat 
hydroquinone (59)
X
MeHN NHz
H*, heat 
hydroquinone
1) 1,methyl-dihydropyrimidlne 
-2,4-dione
(64)
A
2) 1,3-dimethyl-dihydro 
pyrimidine-2,4-dione
Scheme 52
However, in the latter, instead of giving the anticipated mixture of 1 or 3- 
methyldihydropyrimidine-2,4-diones, a mixture of (59) and (64) was obtained. This
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can be explained if the urea undergoes a disproportionation reaction (Scheme 53) prior 
to the reaction with acrylic acid.
ref ux 2hr
Scheme 53
To determine if this was the case N-methylurea (68) was subjected to the reaction 
conditions but in the absence of acrylic acid. Disproportionation would be expected to 
yield both 1,3-dimethylurea (69) and urea. Analysis of the products by NMR 
spectroscopy and TLC indicated that (68) does indeed undergo a disproportionation 
reaction to form (69) (Scheme 53) though urea was not observed although the 
disproportionation explains the presence of (59) in the synthesis of (64). The formation 
of only ((64) rather than (63))can be attributed to the higher nucleophilicity of the urea 
NMe nitrogen atom over NHz nitrogen atom in the initial addition step of the reaction; 
this results in the formation of only one isomer.
To synthesise 3-methyldihydropyrimidine-2,4-dione (63) the following method was 
used (Scheme 54)
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Scheme 54
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In this synthesis, nucleophilic attack at the imide yields N-methylsuccinic diamide, 
which is subjected to oxidative cyclisation using DMF/lead tetra-acetate.
This compound could potentially arise from oxidation of DMPU by both ring and N- 
methyl oxidation, though the probability of formation of this compound is low since it 
requires four oxidations. Given that the substrate will be in large excess, the chances 
of an oxidised product being further oxidised are relatively low. In a biological system, 
the likelihood of multiple oxidations to occur on the same molecule is even lower, 
because the hydrophilicity of the metabolite is greater than the substrate thereby 
making it less likely to occupy the hydrophobic active site in the P450 enzyme.
The synthesis of l-methyltetrahydropyrimidine-2-one (61) was achieved by reaction 
of dicarbonylimidazole with N-methylpropane-1,3-diamine (Scheme 55).
Me
THF
48h
1 -methyl-3,4,5,6-tetrahydro 
pyrimidine-2-oneMe'
Scheme 55
In order for (59) to be formed DMPU must undergo double oxidation. It follows that 
DMPU is initially oxidised to (58), which would subsequently undergo further 
oxidation to (59). Synthesis of the alcohol (58) was carried out using the procedures 
shown in Scheme 56.
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Unfortunately, the purification of this material proved extremely difficult, with the 
compound decomposing on the chromatography column. To ascertain that the 
compound had been made, ^HNMR (Figure 24) and HPLC mass spec (Figure 25) were 
obtained.
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The mass spectrum showed that the compound had the expected mass of 145 for MH^. 
Fragmentation at 127 is due to loss of OH and the peak at m/z=167 can be ascribed to 
(M+Na"*"). Although the compound is not pure, NMR indicates the formation of 
(64). In this spectrum two singlets of 6H Ôh =2.85, 2.90 show the two methyl groups 
(H ,^ H^) (Scheme 61). A triplet of IH at Ôh =4.81 shows H^, and a multiplet at Ôr 
=1.87, 2H shows H® and i f .  Due to the puckered nature of the ring (Scheme 57) it 
can be seen that the OH group has a greater influence over H^ than H .^ This causes a 
down field shift for H^ resulting in a IH doublet of triplets at Ôr =3.54, H  ^ arrives 
upfield from this at with a IH multiplet at Ôr =3.14.
CH
OH
(58)
Scheme 57
Unfortunately, quantitative analysis for (58) could not be obtained due to the difficulty 
in obtaining a pure sample. Nevertheless, comparison of the synthesis reaction mixture 
and that from the model oxidation reaction mixture reveals the presence of a product 
that has an identical retention time for a major unknown in the model system thus 
indicating that the ring oxidised alcohol (58) is probably formed in the model 
oxidations.
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Synthesis of the foimylhydropyrimidinones was accomplished using a Vilsmeier salt 
(Scheme 62)
Cl—^ c i  
Cl
1) l-formyltetrahydropyrimldin-2-one 2)1,3-dlformyltetrahydropyrlmldln-2-one
Scheme 58
Both the mono- and diformylated products were isolated. The monoformylated (60) is 
relatively stable compared to (65) which readily deformylates in water to afford (60). 
The latter does not undergo deformylation to tetrahydropyiimininone and is stable in 
water over a two-day period. This increased stability can probably be ascribed to the 
formyl groups in (65) both being imide-like whereas the formyl group in (60) is more 
amide like, the latter allowing increased delocalisation of the nitrogen non-bonding 
electron pairs over the amide bond system.
3.4 DMPU model studies
DMPU model studies were carried out using a method similar to that used for HMPA. 
HPLC analysis was carried out using a Varian photodiode array. The solvent system 
was as detailed in experimental. Analysis of the reaction mixture reveals that oxidation 
of DMPU takes place in the ring rather than at the methyl groups. This conforms to 
previous studies involving N-methyl-2-pipieridinone although with this latter 
compound methyl group oxidation was observed^ .^
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Single oxidation of the ring to the corresponding alcohol (58) occurs. Unfortunately 
quantitative analysis could not be carried out since a pure sample of this compound 
was not obtained. Further oxidation of the alcohol then occurs, resulting in the 
formation of (59), quantitative analysis of (59) allowed a initial rate graph to be 
constructed (Figure 26). By comparison of these results to that of a graph prepared 
from a standard solution at varying concentrations an extent of reaction of 
approximately 3.5 per cent was determined (experiment carried out as per section 4.5.3 
[TPPFeCl] = 0.001 M, [tBuOOH] = 0.2 M, [DMPU] = 0.2 M)
Initial rate of oxidation of DMPU
1 0 0 0  1
CO 500
♦  initial ra tes
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-500 -J
DMPU/M
Figure 26
A similar ring system, N-methylpiperidin-2-one has been studied.^  ^The observed rate 
of déméthylation for N-methyl-2-piperidinone is 1.7 x 10*^  s'^  and ring oxidation is 
9.4x10*  ^s '\  in DMPU the rate of ring oxidation is 6 x 10'^  s '\ This gives a 
comparative rate of ring oxidation at 15 fold slower for DMPU. These rates may 
explain the lack of oxidative déméthylation from DMPU since in N-methyl-2- 
piperidinone this occurs ~ 5000 fold slower than ring oxidation. Since this compound 
has chemistry similar to DMPU (ring oxidation only 15 fold slower) it can be argued 
that comparable rates may be observed for DMPU. If this is the case any demethylated 
product will not have been observed in the analytical system used.
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3.4.1 AMI semi-empirical molecular orbital calculations
Using the self-consistent field semi-empirical AMI model the heats of formation of 
the postulated carbon-centred radical intermediates and the oxidised products of the 
reactions indicated in Scheme 43 were calculated (Table 3).
Table 3 Heats of formation of (AHf) calculated by the AMI model for DMPU
and its postulated radical and oxidised intermediates
Compound AHf (kcal/mol)
0
V
-29.04
0
V
-4.61
0
V-
-10.33
0
UL.
-73.75
0 OH -78.87
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0VL.
-62.59
■.XX. -64.25V
0 -34.69
V
X. -31.5
Using the calculations below it can be seen that formation of a carbon-centred radical 
on the ring is favoured over that of the N-methyl position. Although the difference in 
heats of formation of the two radicals is only 5.72 kcal/mol, if this diffeence were 
reflected in the activation energies then the rate of formation of the ring oxidised 
intermediate would be 13000 times faster than oxidation of the N-methyl position. 
Thus, these data predict almost exclusive reaction at the ring carbon. Such calculations 
have also correctly predicted the reactivity of cyclic amides.
SmcQk = (XT!h)e-^^*'^^
and InÂ: = ln(kr//i) -  KG* IRT
then lnkj= ln(kT / h ) -  AG *J RT for ring oxidation
and Ink 2= ln(kT IK )- A G y RT for methyl oxidation 
Consequentely, lnk /k2= {A G y RT) -  {A G yR T ) = KAG^yi RT
Assuming that the difference between AHf of the radicals reflects the difference in 
AG ,^
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AAG’^2,1 ~ AH2-AH1 ~ -4.61+10.33 = 5.76 
So, In ki/k2 = 5.76 x (4.18 x 10^)7(8.31 x 303.2) = 9.49 
and k\/k2 = 13227
Interestingly, the data for the putative radical intermediates contrast with those of the 
hydroxylated products where formation of N-hydroxymethylDMPU is 
thermodynamically favoured over the ring hydroxylated product. The model 
experiments described here have shown the formation of ring hydroxylated products in 
the form of singly and doubly oxidised DMPU. Thus, these are the kinetic, rather than 
the thermodynamic products of oxidation by TPPFeCl/^BuOOH
3.5 Further work
3.5.1 Alkynes in C-centred radical trapping
For amides, it has been shown that microsomal oxidation results in N-dealkylation. 
The possible routes of déméthylation are shown in (Scheme 32). This involves either 
electron abstraction from the heteroatom (nitrogen) or H-atom abstraction to form a C- 
centred radical. For the amide DMF, it has been demonstrated that H-atom abstraction 
results in C-centred radical formation. Due to the similarities between the amide, urea 
and phosphoramide functional groups, it was decided that H-atom abstraction would 
also be the most likely route of dealkylation for both HMPA and DMPU. To identify 
whether C-centred radicals are involved in the model reactions an attempt to 
synthesise substrates incorporating an alkyne probe would allow this to be determined.
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Scheme 59, underlines the method development for making amide-derivatised alkyne 
probes. Several routes for the synthesis of alkyne probe derivatives have been 
attempted, it is hoped that this will form the basis for future work in this area.
(A) HO'
3) Alkyne
(B) HO' DIAD
O
THF
1) R
(C) HO HgN
2) NEta
Scheme 59
Route A utilises a strong base to remove a hydrogen atom from the amide nitrogen to 
form an anion; which can undergo substitution reaction using an appropriately 
derivatised butyne. For the phosphoramide derivatives, PMPA was used as the 
equivalent amide. Scheme 60 shows the different butynes and bases used in the 
attempted formation of the phosphoramide derivative (70).
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1) THF, TsO'
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2)BuU
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Scheme 60
In none of the above experiments was the desired phosphoramide derivative made, 
only PMPA being recovered. One possible explanation for the reactions not 
accomplishing the desired transformation is that the nitrogen anion is insufficiently 
nucleophilic to undergo substitution. To improve the strength of the anion different 
bases were used (BuLi, NaH, LDA and ^BuOK) in the hope that by varying the metal 
cation the strength of the anion could be increased. In the event this was not observed. 
Another method of increasing the strength of the anion is by complexing the metal 
cation. Thus TMEDA was employed with the bases derived from lithium salt. Again, 
the reaction failed.
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An alternative approach involved altering the leaving group on the butyne; in this case, 
the tosyl group was replaced by bromine or iodine. In no case was the synthesis 
successful.
For route (B) Scheme 59, a variation of the Mitsunobu reaction was carried out. This 
should have resulted in the coupling of the amide with the alcohol. However, the only 
butyne-substituted product obtained was (71).
N—N
(71)
For route (C), the idea was to form the 4-aminobutyne from the parent alcohol then 
perform a substitution reaction with the phosphoramide acid chloride equivalent. 4- 
Aminobutyne was prepared according to Scheme 61.
H2N2
EtOH
HCl
3-butynyI 4-toluene sulfonate
NH KI DMF 
24 hr reflux (73)
(72)
THF DMF
HgNTsO'
TsCI
NEI3
3hr reflux
EtOHNaNa 
24hr RT
(74) (75) (76)
Scheme 61
In Scheme 61, pathway (A), the N-(3-butynyl)phthalimide (72) is made from a 
Mitsunobu reaction involving phthalimide, 3-butyn-l-ol and DIAD. Unfortunately, the
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following step involving hydrazine and salt formation proved too difficult to purify, so 
the longer approach (Scheme 61, pathway B) was undertaken.
Pathway B involves the conversion of an alcohol to the corresponding tosylate (74); 
this is then converted to an azide (75), which is subsequently reduced to the amine
(76). Formation of the amine was achieved but on a small scale. Attempted coupling 
of the amine to an acid chloride failed but this may be due to the scale, and so may 
work on a larger scale. This line of research was stopped due to a lack of time, but it 
can be seen that the basis for further research has been set in place with (76) having 
been synthesised. This leaves only the coupling of the amine to the relevant acid 
chloride to prepare the desired butynyl derivative. When this is prepared the butynyl 
derivative should be exposed to the same oxidation conditions as those previously 
used for HMPA. When this is achieved analysis of the reaction products will 
determine if a C-centred radical is formed as an intermediate (The formation or 
absence of the relevant cyclised products indicating formation of a C-centred radical).
3.5.2 Investigating the denterinm isotope effect on DMPU
This Study demonstrates that oxidation of DMPU via model studies occurs on the ring. 
Previous studies of amide solvents show how oxidation results in the formation of a C- 
centred radical. DMPU has a similar functional group to amides, hence if DMPU 
forms a C-centred radical during oxidation it is to be expected that H-atom abstraction 
will occur. Such H-atom abstraction must occur at the ring methylene, given the 
observed product analysis. This being the case, an investigation into the deuterium 
isotope effect will add weight as to whether or not H-atom abstraction occurs. DMPU 
is a symmetric molecule, hence there are two sites in the ring with equal opportunity
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for attack. To allow accurate determination of the deuterium isotope effect both need 
to be fully deuterated. The following Scheme shows several possible route of synthesis 
for (77).
A
(82)
(A) UAID4
Carbonyl
O
0  0  ‘-IAID4 OH (DH (C) PBrg ^  MeNHg HN^ diiimidazole '^N
Ether D "  D - T ^ / V ^ D  HgO "  THF "  °  '
D D D D D , D D / , , \ D
(78)
(79) (80)" "(77)
(B)
p
"(81)"
Scheme 62
The above synthèse were attempted using LiAIH4 to determine their feasibility prior to 
carrying out the experiment with expensive LiAlÜ4. In pathway (A) Scheme 62 
reduction of dimethylbarbituric acid was attempted. This did not give the required 
product; in retrospect this reaction is unlikely to work due to the acidic protons lying 
between the two carbonyl groups. These will be removed easier than reduction of the 
carbonyl groups, so negating the desired carbonyl reduction. At this stage, a 
retrosynthetic analysis was undertaken. According to this, the desired deuterium 
insertion is carried out by reduction of diethyl malonate. This reaction was carried out 
using LiALH4 and afforded (78) in a 52 per cent yield. Using this latter material, it is 
possible to follow two routes. The most obvious is pathway (C) Scheme 62, 
bromination of the diol (78) to (79), followed by conversion to the diamine (80) and 
finally coupling with carbonydiimidazole to form the desired product. Bromination of 
the diol was successful but the following conversion to the amine gave a large mixture
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of products. Because of this, pathway (B) Scheme 62 was attempted. This allows 
direct coupling of the diol (78) to dimethylurea (81) affording the desired product.
This was attempted and afforded the desired product in 42 per cent yield. The final 
deuterated product was not synthesised due to a lack of time but the methodology has 
been set in place for future work in this area. This is an adaptable methodology since 
the diethyl malonate may be replaced with 3-hydroxypropanoic acid ethyl ester, this 
allows reduction with LiAlD4 to the alcohol at only one site. Final coupling of this will 
give DMPU but with only one ring site deuterated.
Future work will undoubtedly focus on microsomal oxidation of DMPU. To study the 
deuterium isotope effect with microsomal oxidation consideration must be given to 
how microsomes attack specific sites on a molecule. Previous work with amides has 
shown on that although ring oxidation is preferred in model studies, when microsomal 
oxidation is carried out significant amounts of N-methyl oxidation also occurs. To 
allow determination of the deuterium isotope effect on N-methyl oxidation a method 
was developed where deuterium was incorporated on to the N-methyl groups (Scheme 
63)
1) B u liHN NH HN
(82) (83)
Scheme 63
The above synthesis was carried out but only (83) was obtained. Further reaction of 
this compound would afford (82). This methodology can also be adapted to making
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DMPU with deuterium incorporated at one methyl site and hydrogen at the other. This 
could be accomplished by replacing tetrahydropyrimidinone with 1- 
methyltetrahydropyrimidin-2-one.
Analytical techniques and synthetic protocols should make the final stages of this 
project easily obtainable for future workers in this area. This would be a profitable line 
of research with results hopefully giving insight into why DMPU is non-toxic. Using 
this knowledge should allow the development of new, safer solvents.
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4.0 Experimental
4.1 HPLC
Separation of amides was achieved using a 5pm CIS 25cm Waters Symmetry column 
with an eluent system of 50% acetonitrile, 50% H2O (flow rate Iml/min, loop: 20pl). 
Identification was achieved by comparison of retention times and diode array UV-VIS 
spectra with those of synthetic standards.
Separation of phosphoramides was achieved using a 5pm 25cm PLRP column with an 
eluent system: time t=0 to 5 min, 5% acetonitrile, 95% H2O; time t=5.1 to t=25.0 min, 
10% acetonitrile, 90% H2O; time t=25.1 to t=35 min, 100% acetonitrile (flow rate 
Iml/min, loop: 20pl). Identification was achieved by comparison of retention times 
with those of synthetic standards.
4.2 Gas Chromatography
Separation of phosphoramides was achieved using a Perkin Elmer chromatograph with 
direct on-column injection (column: BP5 20m x 0.5mm 0.22pm i.d.; gradient: 
isothermal at 70 °C for 1 minute, thermal gradient from 70 °C to 300 °C with a ramp 
rate of 10 °C/min, isothermal at 300 °C for 10 min; detector: FID at 250 °C; injection 
temperature 210 °C).
4.3 Spectroscopy
NMR Spectra were recorded using JOEL Lamda 300 spectrometer operating at 300 
MHz for chemical shifts, Ô, are reported in p.p.m. from tetramethylsilane and
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coupling constants are reported in Hz. IR spectra were recorded using a Nicolet 205 
FTIR spectrometer.
4.4 Solvents and Reagents
All chemicals were obtained from commercial sources.
Solvents were dried by CaH and distilled onto molecular sieves.
4.5 Synthesis
For all compounds purity was determined by NMR where only the peaks relevent 
to the compound were observed indicating >96% purity.
N-Methylbenzamide^^ (50)
To a solution of methylamine (0.33 mol, 10.25 g,) and NaOH (0.2 M, 400 cm^), 
benzoyl chloride was added drop-wise with stirring. After stirring for 10 min the N- 
methylbenzamide product was extracted with DCM and recrystalised from EtOH/HzO 
to give long white crystals, 
m.p. 81°C litm.p. 82°C 
Yield 86%
0h(CDC13): 3.01 (3H, d, 7=5.1, N-Me), 6.24 (IH, s, N-H), 7.39-7.52 (3H, m, PhCO) 
7.75 (2H, d, 7=5.0, PhCO)
ôc(CDCl3): 26.85 (NMe), 126.82 128.56 {ortho/meta-Vh), 131.35 (para-Ph), 143.5
(ipso-Vh), 170.00 (NCO)
m/z: 135 (PhCON+CHz), 105 (PhCO+), 77 (Ph+)
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N-Formyl-N-methylbenzamide^^ (51)
Dimethylbenzamide (500 mg, 0.0336 mol) and TPPFeCl (23.7 mg, 33.6 pmol) were 
dissolved in dry DCM (25 cm^). fer^-Butylhydroperoxide (20.74 mg, 1.65 mmol) was 
added. The mixture was heated to 30 °C with agitation. At 2 ,4 , 6 and 8 h intervals 
further portions of rerT-butylhydroperoxide (1.65 mmol) were added. The mixture was 
left overnight, treated with activated charcoal, filtered and purified using silica gel 
column chromatography (hexane/ethyl acetate 5:2) to yield a viscous oil.
Yield 7.3%
5 h(CDC13): 3.21 (3H, s, N-Me), 7.38 (5H, m, PhCO) 8.92 (IH, s, HCO) 
0c(CDCl3):27.48 (N-Me), 128.80 128.9 {ortho/meta-Vh), 132.16 (para-Ph), 133.40 
{ipso -Ph), 164.36 (NCOH), 172.34 (CCON)
Vmax/cm'  ^ 1692 (C=0)
.4.5.1 HMPA derivatives
N-ChloromethylpentamethyIphosphoramide(55)
Under nitrogen, pentamethylphosphoramide (0.02 mol, 3.3 g) was dissolved in 
chlorotrimethylsilane (TMSCl ) (50 cm^). Paraformaldehyde (2 g) was then added and 
the solution heated under reflux for 2 h. The solution was filtered and TMSCl removed 
under reduced pressure to yield N-chloromethyl-N-pentamethylphosphoramide 
quantitatively in 100% conversion to yield a clear viscous oil.
Yield 100%
0h(CDC13): 2.72 (12H, d, 7=10.1, N-Mez), 2.84 (3H, d, 7=13.9, N-Me), 5.31(2H, d,
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20.3, NCHzCl)
N-Alkylphosphoramides^°^
The appropriate amine (0.179 mol) was dissolved in dry ether (40 cm^) at -10°C. To 
this was added dropwise an ethereal solution of tetramethylphosphorodiamidic 
chloride (0.059 mol, 4.94 g). The solution was warmed to room temperature and 
stirred for 2-3 h. The resulting hydrochloride salt was filtered off, the ether solution 
washed with water, then dried (MgS04), and the ether removed under reduced 
pressure. The crude mixture was separated by column chromatography 
(chloroform/EtOH 7:1 v/v).
Pentamethylphosphoramide^°^(42)
Yield (5.8g, 68.0%) as a clear liquid
5h(CDC13): 2.08 (lH,s, N-H), 2.47 (3H, dd, 7=11.5,15.8, N-Me), 2.56 (12H, d, 
7=9.52, N-Mez)
0c(CDCl3):27.12 (N-Me), 36.77 (N-Mez)
Vrnax/cm'^  325 Iw (H-N), 2948 (C-H), 1218s (P=0), 776s (P-N)
N-Formylpentamethylphosphoramide^°^ (45)
To an ice-cold solution of HMPA (1.8 g, 0.01 mol) in HzO (20 cm^) a solution of 
KMn04 (3.2 g, 0.2 mol) in HzO (100 cm^) was quickly added. The mixture was 
allowed to stir for 5 min then the ice bath was removed and the solution left to stir at
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room temperature for 45 min. A cold solution of NazSOs (5 g, 0.04 mol) in HzO (50 
cm^) was added, followed by 2M HzS04 (dropwise) till the solution turned clear 
(approx. 30 cm^). The solution was extracted with chloroform (3 x 50 cm^), the 
organic extract washed with brine (1 x 20 cm^), dried (MgS04) and evaporated under 
reduced pressure to yield the product as a clear liquid.
Yield 66%
0h(CDC13): 2.64 (12H, d, 7=10.1, N-Mez), 2.65 (3H, d, 7=8.6, N-Me), 8.65 (IH, s, 
NHCO)
0c(CDCl3): 27.50 (N-Me), 36.54 (N-Mez), 165.34 (CO)
Vrnax/cm'^  2816w (C-H), 1685s (HNC=0), 1284s (P=0), 755m (P-N)
Bis(dimethylaiiiino)-N-(/cr^-butylhydroperoxymethyl)-N-methylphosphoraimde
(54)
PMPA (0.5 g, 0.003 mol) was added to a 37% formaldehyde solution (0.73 g, 0.009 
mol). This solution was allowed to stir at room temperature for 24 h. The solvent was 
removed under reduced pressure, then ^grT-butylhydroperoxide (3 cm^) was added, 
followed by two drops of TFA. The solution was allowed to stir for a further 3 h, after 
which the solvent was removed under reduced pressure to yield to product as a clear 
liquid.
Yield 95%
0h(CDC13): 1.21 (12H, s, 0 -0 -C(CH3)3), 2.64 (8H, d, 7=9.51, P(NMez)z, 2.74 (3H, d, 
7=8.25, PNMeCHzOOtBu) 4.79 (2H, d, 4.77,7=11.73, NCHzOOtBu 
0c(CDCl3): 26.38 (C(CH3)), 34.35 (NCH3), 36.81 (N(CH3)z, 80.50 (C(CH3)), 92.15 
(NCHzOOC)
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Vrna^ /cm-' 2800 (C-0), 1365s (C(CH3 )3), 1250s (P=0), 750m (P-N),
Accurate Mass ES+, [M+H]: obtained 268.1793, expected 268.1790
3-Butynyl 4-toluenesulfonate^°^ (74)
Under a nitrogen atmosphere, 3-butyn-l-ol (0.1 mol, 7.01 g) and triethylamine (0.11 
mol, 11.1 g) were dissolved in dry THE (100 cm^). To this, a solution of THE 
containing 4-toluenesulfonyl chloride (0.1 mol, 19.1 g) was added dropwise and the 
reaction mixture was heated at reflux for 2 h. After cooling a white precipitate was 
filtered and the solvent removed under reduced pressure, to give a dark oil. The oil 
was resuspended in ether (50 cm^), washed with IM hydrochloric acid (2 x 20 cm^), 
saturated sodium hydrogen carbonate (2 x 20 cm^) and washed again with water (2 x 
20 cm^). The organic layer was dried (MgS04) and the solvent removed under reduced 
pressure. The resultant oil was purified by column chromatography on silica (10:1 
hexane/EtOAc) to give the desired product as a clear pale yellow liquid.
Yield 74%.
5 h(CDC13):1 .95  (IH, t, 7=2.6, CH), 2.43 (3H, s. Me), 2.58 (2H, dt, 7=2.6 7.7, 
CHzCCH), 4.06 (2H, t, 7=7.8, CHzO), 7.28 (2H, d, 7=8.4, meta-Vh), 7.78 (2H, d, 
7=8.3, ortho-VM)
5c(CDCl3): 19.43 (CHzCCH), 21.64 (Me), 67.39 (OCHz), 70.74 (CHzCCH), 78.34 
(CHzCCH), 127.96 129.88 ortho/meta Vh), 132.81 144.99 (ipso-Ph)
N-(3-ButynyI)phthaIimide''‘’“ '(72)
3-Butynyl 4-toluenesulfonate (0.067 mol, 14.2 g), potassium iodide (3.6 mmol, 0.6 g) 
and potassium phthalimide (0.074 mol, 13.65 g) were dissolved in dry
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dimethylfomiamide (200 cm^) and refluxed for 24 h under a nitrogen atmosphere. 
After cooling, the solution was poured onto crushed ice (200 g). Extraction with 
diethyl ether (4 x 200 cm^) was followed by washing with sodium hydroxide (200 
cm^), water (2 x 100 cm^), and 0.5M hydrochloric acid (200 cm^). The organic layer 
was dried (MgS04) and the solvent removed under reduced pressure to leave the 
product which was recrystallised from diethyl ether/hexane as a white solid. 
m.p. 134-135 °C lit m.p. 133-134 °C 
Yield 86%
0h(CDC13): 1.95 (IH, t, 7=2.55, CHzCCH), 2.6 (2H, dt, 7=2.58, 6.96, NCH2CH2), 3.85 
(2H, t, 7=6.96, NCHz), 7.75 (4H, m. Aryl)
0c(CDCl3): 18.32 (CHzCCH), 36.49 (NCHz), 70.22 (CCH), 80.01 (CHzCCH) 123.36 
(Aryl CH), 132.23 (Aryl CHCCO), 134.02 (Aryl CH), 172.20 (NCO)
3200s (-C=C-H)2140w(C=C), 1650 (C=0)
4-Aminobutyne hydrochloride^ (73)
NaN3 (5.62 g, 117.2 mmol) was added to a solution of 3-butynyl 4-toluenesulfonate 
(5.25 g, 23.44 mmol) in dry dimethylformamide (30 cm^), and the resulting suspension 
was stirred for 24 h. The mixture was partitioned between water (100 cm^) and diethyl 
ether (100 cm^), the aqueous phase was extracted with diethyl ether (50 cm^) and the 
combined organic phase thoroughly washed with water (5 x 25 cm^), dried with 
MgS04, and concentrated to remove most of the ether. The resulting clear liquid 
containing 3-butynyl azide was used without further purification. This solution was 
dissolved in methanol (75 cm^), SnCl2.2H20 (10.58g, 46.88 mmol) was added, the 
solution was stirred at room temperature for 24 hr, after which time the solvent was
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evaporated under reduced pressure, and the residue dissolved in 10% aqueous NaOH. 
This solution was extracted with dichloromethane (5 x 40 cm^). The combined organic 
phase was dried (Na2S04), then a saturated solution of HCl in diethyl ether (20 cm^) 
was added, and the resulting precipitate collected by filtration affording the required 
hydrochloride. The filtrates were concentrated to dryness to afford additional 
hydrochloride as yellow prisms.
Yield 21%
0h(D20): 2.42 (IH, t, 7=1.5, CH), 2.54 (2H, dt, 7=1.5,4.2, CH2CH), 3.10 (2H, t, 
7=5.1, NCH2)
6c(D20): 17.66 (CH2CCH), 39.00 (NH3CH2), 73.38 (CH), 80.24 (CH2CCH)
Vmax/cm*^  3200s (-C=C-H) 2140w (C=C), 2700 (-NH2+)
4.5.2 DMPU Derivatives
l-MethyItetrahydropyrimidin-2-one^ (61)
Under nitrogen, N-methyl-1,3-propanediamine (0.02 mol, 1.48 g) was dissolved in 
THF (10 cm^) and carbonyldiimidazole (0.02 mol, 3.24 g) dissolved in THF (30 cm^) 
was added dropwise with stirring. The solution was allowed to stir at room 
temperature for 48 h, then acidified using 2M HCl. Both THF and water were removed 
under reduced pressure and the crude mixture washed through silica plug with MeOH 
to afford 1 -methyltetrahydropyrimidin-2-one.
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m.p. 91-92 °C lit m.p. 90-92 °C 
Yield 46%
8h (CDCI3 ): 1.88(4H, quintet, 7=5.7 CH2 CH2 CH2), 2.86 (3H, s, N-Me), 3.18 (2H, dt, 
7=2.6,5.7, HNCH2 CH2), 3.24 (2H, t, 7=5.9, CH2CH2NMe ), 4.92 (IH, s, N-H) 
ScCCDCU): 21.53 (CH2 CH2CH2 ), 35.31 (N-Me), 40.02 (MeN-CH;), 47.45 (HN-CH2), 
118.69 (CO)
Vmax/cm'' 3387b (N-H), 1650 (NOON)
1,3 Dlmethyl-5,6-dihydropyriiiiidme-2,4-dlone“* (59)
1,3-Dimethylurea (0.1 mol, 8.81 g), acrylic acid (0.05 mol, 3.6 g) and hydroquinone 
(0.0004 mol, 0.05 g) were added together under N2 then heated at reflux for 2 h. After 
cooling the reaction was quenched in H2O (20 cm^) and extracted with chloroform 
(5x20 cm^). The combined extracts were washed with K2CO3 (0.5M, 20 cm^), dried 
(MgS04) and the solvent removed under reduced pressure to afford a crude mixture 
that was purified by column chromatography (hexane/EtOAc 1:1) to give 1,3- 
dimethyl-5,6-dihydropyrimidine-2,4-dione as white prisms. 
m.p. 47-49 °C lit m.p. 48-49 °C
Yield 54.8%
5h(CDC13): 2.71 (2H, t, 7=6.9, COCH2), 3.03 (3H, s, CONMe), 3.15 (3H, s, 
CONMeCO), 3.34 (2H, t, 7=6.9, NMeCH2 )
0 c(CDCl3 ): 27.81 (OCNMeCO), 31.67 (OCCH2), 36.11 (0 CNMeCH2), 43.15 
(MeNCH2), 153.23 (CH2NCO), 169.63 (NCON)
Vmax/cm' 1714s (NCOC), 1661s (NCON)
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l-Methyl-5,6-dihydropyrimidine-2,4-dione^(64)
N-Methylurea (0.1 mol, 7.4 g), acrylic acid (0.05 mol, 3.6 g) and hydroquinone 
(0.0004 mol, 0.05 g) were added together under N2 then heated at reflux for 2 h. After 
cooling the reaction mixture was quenched in H2O (20 cm^) and extracted with 
chloroform (5 x 20 cm^). The combined chloroform extracts were washed with K2 CO3 
(0.5 M, 20 cm^), dried (MgS04) and the solvent removed under reduced pressure to 
afford a crude mixture that was purified by column chromatography (hexane/EtOAc 
1:2, EtOAc) to yield white prisms. 
m.p. 129-130 °C lit m.p. 129-130 °C 
Yield 21%
8h(CDC13): 2.65 (2H, t, 7=6.8, COCH2), 2.98 (3H, s, N-Me), 3.4 (2H, t, 7=6.9, 
HNCH2 ), 8.64 (lH,s, N-H)
0c(CDCl3) : 30.86 (OCCH2), 34.81 (N-Me), 43.99 (NCH2), 153.29 (NCOCH2),
170.16 (NCONCO)
Vmax/cm'^  3220 (N-H), 1712 (NCON), 1700 (NCOC)
3-MethyI-5,6-dihydropyrimidine-2,4-dione^ ^  ^ (63)
Succinimide (10 g) was shaken with aqueous methylamine (25 cm ;^ 33%). On 
standing, the solution deposited a crystalline solid, which was collected and 
recrystallised from ethanol to give N-methylsuccinamide as prisms. N- 
Methylsuccinamide (1.0 g) was then stirred at 60-70°C for 2 h with lead tetra-acetate
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(3.5 g) in dimethylformamide (10 cm^), and the mixture evaporated under reduced 
pressure. Extraction of the residue with hot ether, and crystallisation of the extracted 
material from ethanol gave the title compound (0.51 g). 
m.p. 171-173 °C lit m.p. 170-172 °C 
Yield: 50%
8h(CDC13): 2.73 (2H, t, 7=6.78, OC-CH2), 3.17 (3H, s, N-Me), 3.41 (2H, dt, 7=2.76, 
6.78, NH-CH2), 5.96 (IH, bs, N-H)
8c(CDCl3):27.03 (OCCH2), 31.45 (N-Me), 35.32 (NCH2), 157.0 (NCOCH2), 169.79 
(NCONCO)
Vmax/cm'^ 3210 (N-H), 1750 (NCON), 1700 (NCOC)
Synthesis of N-FormyIamides“ ^
Dimethylformamide (0.006 mol, 0.44 g) was treated dropwise, under cooling and 
stirring, with phosphoryl chloride (0.008 mol, 1.23 g). The mixture was stirred at room 
temperature for 15 min, then cooled using an ice bath before the appropriate amide 
(0.003 mol) in acetonitrile (10 cm^) was added dropwise. The reaction mixture was 
then allowed to warm to room temperature, then heated to reflux for 15 min. The 
reaction mixture was cooled, and quenched with ice, then extracted with chloroform. 
The organic layer was washed to neutrality with sodium hydrogen carbonate solution, 
dried (MgS04) and concentrated under reduced pressure. The crude mixture was 
purified by column chromatography (DCM containing 1.5%MeOH)
l,3-DiformyItetrahydropyriinidin-2-one (65) 
m.p. 108-109 °C
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Yield 2.3%
ShCCDCIs): 2.01 (2H, quintet, 7=6.1), 3.68 (4H, t, 7=6.1), 9.43 (2H, s) 
ôcCCDCls): 19.92 (CH2CH2CH2), 39.31 (NCH2), 153.18 (NCON), 161.90 (NCOH) 
Vmax/cm'^  1662 (C=0)
l-FormyItetrahydro-pyrimidin-2-one (60) 
m.p. 90-95 °C 
Yield 0.4%
6h(CDC13): 1.96 (2H, quintet, 7=5.9, CH2CH2CH2), 3.34 (2H, dt, 7=2.6, 6.0, NHCH2), 
3.67 (2H, t, 7=6.1, CONCH2), 6.35 (IH, s, NH), 9.35 (IH, s, COH)
5c(CDCl3): 20.79 (CH2 CH2 CH2 ), 38.97 (HNCH2 ), 39.77 (CONCH2 ), 153.95 
(NCON), 162.43 (NCOH)
Vmax/cm-^  3240 (NH), 1690 (CO)
4-Hydroxy-l,3-dimethyltetrahydropyrimidin-2-one^ (58)
To a stirred solution of l,3-dimethyldihydropyrimidine-2,4-dione (1.6 g, 11.3 mmol) 
in toluene (20 cm^) was added DIBAL IM (12 cm ,^ 12 mmol) dropwise. The reaction 
mixture was stirred for 6 h (endpoint determined by HPLC). Methanol was added to 
quench the reaction then the mixture was filtered, the toluene removed under reduced 
pressure and the resultant crude product analysed by HPLC mass spectrometry 
m/z: 167 (M-Na), 145 (M+), 127 (M+-OH2)
8h(CDC13): 1.87 (2H, m, CH2CH2CHOH), 2.85 (3H, s, N-Me), 2.90 (3H, s, 
H20CNMe), 3.14 (IH, m, NMeCHH), 3.54 (IH, dt, 7=4.2, 12.1, NMeCHH), CHOH, 
4.81 (IH, t, 7=3.0, OCHN)
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1,3-Dibromopropane (79)
Phosphorus tribromide (5.13 g, 0.019 mol) and 1,3-propanediol (1.12 g, 0.014 mol) 
were mixed at 0 °C and permitted to react slowly as the temperature rose. The mixture 
was stirred at 125 °C for 3 h, then allowed to cool; 10 cm  ^of water were added and a 
small amount of orange precipitate was removed by filtration. The filtrate was 
extracted 4 times with 20 cm  ^of DCM and the combined organic fractions were dried 
over MgS04; 1,3-dibromopropane was isolated as a clear liquid without further 
purification.
Yield 82%
8h(CDC13): 2.40 (2H, quintet, 7=4.9,CH2CH2CH2), 3.57 (4H, t, 7=4.8, CH2CH2CH2)
1,3-PropanedioI^^  ^ (78)
Diethylmalonate (3.5 g, 0.016 mol) in diethyl ether (lOcm^) was added dropwise to 
lithium aluminium hydride (2 g, 0.53 mol) in ether (50 cm^) and the reaction mixture 
refluxed for 2 h after addition was complete. Water (5 cm^) was added cautiously, 
followed by ION-H2SO4 (40 cm^). The aqueous solution was saturated with sodium 
chloride and extracted with diethyl ether. The organic fractions were combined, dried 
with MgS04 and the solvent removed to afford the desired product as a clear liquid. 
Yield 43%
0h(CDC13): 1.79 (2H, quintet, 7=5.5, CH2CH2CH2), 3.64 (2H, s, OH), 3.81 (4H, t, 
7=5.3, CH2CH2CH2)
l,3-Dimethyl-3,4,5,6,-tetrahydro-2(lH)-pyrimidinone (57)
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1,3-Propanediol (10 g, 0.13 mol) and 1,3-dimethylurea (11.56 g, 0.13mol) were added 
together, the reaction mixture was then heated for 24 h at 160 °C. The reaction mixture 
was distilled under reduced pressure to afford the desired product as a clear liquid 
Yield 64%
0h(CDC13): 1.76 (2H, quintet, 7=5.7, CH2CH2CH2), 2.73 (6H, s, NMe), 3.76 (4H, t, 
7=5.5, NCH2)
l-(Trideuteromethyl)tetrahydropyrimidin-2-one (83)
Under nitrogen, tetrahydropyrimidinone (1 g, O.Olmol) was added to dry toluene (50 
cm^). Whilst stirring BuLi (0.011 mol) was added and the mixture stirred for 30 
minutes. Iodomethane-d3 (2.9 g, 0.02 mol) was then added dropwise. The solution was 
stirred for a further 24 h, after which water (2 cm^) was added. The resultant solution 
was filtered, solvent removed under reduced pressure and purified by column 
chromatography (10% MeOH in EtOAc). 
m.p. 90-91 °C 
Yield 39%
8h(CDC13): 1.93 (2H, quintet, 7=6.0, CH2CH2CH2 ), 3.21 (2H, t, 7=6.0,
CH2CH2NMe), 3.27 (2H, dt, 7=2.6, 5.5, HNCH2CH2)
5c(CDCl3): 21.19 (CH2CH2CH2), 30.92 (N-Me), 40.51 (MeN-CH2), 47.34 (HN-CH2), 
118.72 (CO) 
m/z: M  ^= 118
4.5.3 Model Study reactions^ ^
For N,N-dimethylbenzamide
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5,10,15,20-Tetraphenyl-21H,23H-porphine iron(III) chloride (0.001 M) and substrate 
(0.2M) were allowed to stir in DCM (10 cm^) at 30°C for 10 min; tert- 
butylhydroperoxide (170 pi, 0.2M in DCM) was then added. At regular intervals a 100 
pi aliquot was quenched in methanol (200 pi). This was subsequently treated with IM 
methanolic KOH (200 pi), after a further 30 min, the solution then neutralised with 
IM methanolic HCl (200 pi). The treated aliquot was evaporated under nitrogen, 
resuspended in acetonitrile and analysed by either HPLC or GC
For all other substrates
The above methodology was followed, but the 100 pi aliquot was made up to 1 cm  ^
using MeOH and did not undergo the base/acid treatment.
Accuracy
For all model study experiments each sample was tested twice. This gave an error of ± 
5%.
4.5.4 Molecular orbital calculations
Structural determination and heats of formation (AHf) for the cyclic ureas and their 
postulated intermediate radicals, were calculated using the semi-empirical AMI self- 
consistent-field molecular-orbital program within the MOP AC package. Radical
structures were determined using unrestricted Hartree-Fock calculations. All the 
structures were geometrically optimised using the Broyden-Fletcher-Goldfarb-Shanno
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procedure. Computations were performed using a Silicon Graphic Indy workstation 
computer.
Differences in the heats of formation between the parent urea and the radical 
intermediate (AAHf) were used as an estimate for the energy of activation Ea, from 
which relative rate constants could be calculated as seen on p 52-53.
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